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ABSTRACT

Infusions of the nonselective dopamine agonist

R(-)-propylnorapomorphine

(NPA)

into the dorsal striatum

of preweanling rats attenuates kappa opioid-mediated

locomotor activity. The purpose of this thesis was to
ascertain which dopamine receptor subtype
responsible for this effect.

a)

(Dl or D2)

is

It was hypothesized that

Dl, but not D2, receptors in the dorsal striatum

underlie NPA's ability to attenuate the kappa
opioid-mediated locomotor activity of preweanling rats,

and b) microinjecting SKF38393
quinpirole

(a Dl agonist),

and not

(a D2 agonist), would attenuate kappa

opioid-mediated locomotion. To test these hypotheses,
cannulae were bilaterally implanted into the dorsal
striatum of preweanling rats on postnatal day

(PD)

16.

In

Experiment 1, the dopamine receptor alkylating agent

N-ethoxycarbonyl-2-ethoxy-1, 2-dihydroquinoline

(EEDQ) was

administered bilaterally into the dorsal striatum on PD 17
(EEDQ was not utilized in Experiment 2). On PD 18, NPA
(Experiment 1)

and SKF38393 or quinpirole

(Experiment 2A)

were infused into the dorsal striatum and the ability of

these drugs to inhibit U50488

(a kappa opioid agonist)

induced locomotor activity was measured. Results showed
that a) EEDQ does not block NPA's ability to attenuate the

iii

kappa opioid-mediated locomotor activity of preweanling

rats, and b) neither SKF38393 nor quinpirole attenuated

U50488-induced locomotion. These novel findings suggest
that preweanling rats do not respond to dorsostriatal

infusions of EEDQ in same manner as adult rats. Second,
selective stimulation of DI or D2 receptor is not
responsible for attenuating the U50488-induced locomotor
activity of preweanling rats. Our findings suggest that a

synergistic interaction between dorsostriatal DI and D2

receptors may be responsible for attenuating the kappa
opioid-mediated locomotor activity of preweanling rats.

iv

ACKNOWLEDGMENTS
I would like to thank Dr.

Sanders A. McDougall for

all the guidance and support that he has provided me
during this thesis preparation and throughout my graduate
studies.

I am also very grateful for all the help and

expertise that Dr. Cynthia A. Crawford has shared with me
throughout this thesis and during my graduate work.

I

would also like to thank Dr. Matt L. Riggs for his support

and advice during the thesis preparation.

v

TABLE OF CONTENTS

ABSTRACT ................................................. iii
ACKNOWLEDGMENTS .........................................

v

LIST OF FIGURES .......................................

x

CHAPTER ONE:

1

INTRODUCTION ...............................

CHAPTER TWO: KAPPA OPIOID RECEPTORS
Introduction................

4

Kappa Opioid Receptor Subtypes ....................

6

Kappa Opioid Receptor Localization

.............

7

Kappa Opioid Receptor Ligands .....................

9

Ontogeny of Kappa Opioid Receptors

.............

11

Introduction .......................................

14

Structure and Subtypes of Dopamine Receptors ......

15

Distribution of Dopamine Receptors

.............

16

Colocalization of DI and D2 Receptors............

20

Dopamine Receptor Stimulation and Dopamine
Transmission .......................................

21

Ontogeny of Dopamine Receptors ....................

23

CHAPTER THREE: DOPAMINE RECEPTORS

CHAPTER FOUR: BASAL GANGLIA

Introduction .......................................

27

Striatum................... ........................

29

Globus Pallidus ....................................

31

Subthalamic Nucleus ................................

32

Substantia Nigra Pars Reticulata ..................

33

vi

Entopeduncular Nucleus ............................

35

Substantia Nigra Pars Compacta ....................

36

Summary.............................................

37

CHAPTER FIVE: DOPAMINE MEDIATED BEHAVIOR
Introduction .......................................

39

Systemic Administration of Dopamine Agonists ....

39

Precision Targeted Intracranial
Microinjection of Dopamine Agonists

42

..............

Microinjection of Dl Agonists ...............

42

Microinjection of D2 Agonists ...............

43

Microinjection of Nonselective or
Indirect Agonists . ............................

44

D1/D2 Synergism....................................

45

Neurochemical and Behavioral Effects of
Irreversible Dopamine ReceptorAlkylation .........

47

Ontogeny of Dopamine-Mediated Behavior ...........

50

CHAPTER SIX: KAPPA OPIOID-MEDIATED BEHAVIOR
Introduction .......................................

53

Adult Rats and Mice: Unlearned Motor
Movement............................................

54

Systemic Kappa Opioid Administration:
Striatal Actions .............................

54

Central Kappa Opioid Administration:
Nigral Actions ................................

56

Summary.......................................

57

Preweanling Rats andMice: Overview ...............

58

CHAPTER SEVEN: CONCLUSION

.............................

vii

61

CHAPTER EIGHT: METHODS
Experimental Procedures ...........................

66

Subjects....................................

66

Apparatus.....................................

66

Drugs.........................................

67

Surgery.......................................

67

Microinjection Procedure .....................

68

Behavioral Procedures .............................

69

Experiment 1..................................

69

Experiment 2.................................

70

Experiment 2A.................................

70

Histology...........................................

72

Statistical Analysis ..............................

72

CHAPTER NINE: RESULTS

Experiment 1.......................................

77

Habituation (Time Blocks 1-4) ................

77

U50488 Systemic Treatment (Time Blocks
5-8) ...........................................

77

Dorsostriatal NPA Infusions (Time Blocks
9-16) .........................................

79

Experiment 2A......................................

84

Blocks 1-4) ................

84

U50488 Systemic Treatment (Time Blocks
5-8) ...........................................

84

Omnibus ANOVA Including SKF38393 and
Quinpirole Groups(Time Blocks 9-16) .........

84

Habituation (Time

viii

Dorsostriatal SKF38393 Infusions (Time
Blocks 9-16) ..................................

85

Dorsostriatal Quinpirole Infusions (Time
Blocks 9-16) ..................................

85

CHAPTER TEN: DISCUSSION
Effects of U50488 on the Locomotor Activity
of Preweanling Rats................................

89

Effects of Dorsostriatal NPA Infusions on
U50488-Induced■Locomotion .........................

90

Inability of EEDQ to Attenuate NPA-Induced
Behaviors...........................................

91

Effects of Dorsostriatal Infusions of DI and
D2 Agonists........................................

92

Neuronal Mechanisms Responsible for
Dopamine/Kappa Opioid Interactions ...............

93

Effects of Dorsostriatal Infusion of
Quinpirole on the Locomotor Activity of
Preweanling Rats...................................

95

DorsostriatalInfusions: SKF38393 ..................

97

Paradoxical Actions of EEDQ in Preweanling
Rats................................................

97

Conclusion .........................................

101

REFERENCES................................................ 103

ix

LIST OF FIGURES

Figure 1. The Circuitry of the Basal Ganglia..........

28

Figure 2. Proposed Independent Variables for
Experiment 1 (2x2x4 Design) .............

74

Figure 3. Representation of the Timeline for
Experiment 1..................................

75

Figure 4. Diagram of Independent Variables for
Experiment 2A (2 x 7 Design) ................

75

Figure 5. Representation of the Timeline for
Experiment 2A.................................

76

Figure 6. Mean Distance Traveled Scores of
DMSO-Pretreated Rats during the Testing
Session.......................................

82

Figure 7. Mean Distance Traveled Scores of
EEDQ-Pretreated Rats during the Testing
Session.......................................

83

Figure 8. Mean Distance Traveled Scores of Rats
Receiving Infusions of SKF38393 during
the Testing Session..........................

87

Figure 9. Mean Distance Traveled Scores of Rats
Receiving Infusions of Quinpirole during
the Testing Session..........................

88

x

CHAPTER ONE
INTRODUCTION

Behavior can vary qualitatively or quantitatively

depending on the developmental stage in which it is
assessed. These behavioral differences are often

reflective of neurobiological changes in the central

nervous system that take place across ontogeny.

Understanding these neurobiological changes may provide

important insight into a variety of developmental
pathologies such as attention deficit hyperactivity
disorder, pediatric bipolar disorder, pediatric
obsessive-compulsive disorder, and Tourette's syndrome.

The basal ganglia is a prominent network of brain

structures that modulates various behaviors, including
motor control, motivation and reward,

cognitive processes,

and learning. The basal ganglia's neuronal circuitry

undergoes substantial maturational changes, as the

interaction of various neurotransmitter systems is
responsible for many ontogenetic behavioral effects. One

of the more prominent circuits within the basal ganglia is

comprised of dopamine neurons of the nigrostriatal
pathway.

Stimulation of the dopamine system results in

quantitatively different behavioral effects across

1

ontogeny.

For example, psychostimulant treatment causes a

more robust locomotor response in adult rats than
preweanling animals

(McDougall, Arnold,

McDougall, Duke, Bolanos, & Crawford,

& Nonneman,

1990;

1994; McDougall,

Rodarte-Freeman, & Nazarian, 1999; Moody & Spear,

1992).

Similarly, direct dopamine agonists produce progressively

more robust behavioral effects as the animal matures
(Broaddus & Bennett,
Walters,

1990; Hedner & Lundborg,

1985; Lin &

1994; Moody & Spear, 1992; Shalaby & Spear,

1980).

In addition to the dopaminergic system,

kappa opioid

receptors play an important role in basal ganglia
functioning.

In comparison to the quantitative ontogenetic

differences observed after dopaminergic stimulation,
activation of kappa opioid receptors causes behavioral

effects that vary qualitatively across ontogeny. One of

the most compelling examples of a qualitative change in

drug responsiveness is the paradoxical locomotor response

after treatment with a selective kappa opioid agonist

(e.g., U50488). Specifically, systemic administration of
U50488 attenuates the locomotor activity of adult rats,
while paradoxically causing a dramatic increase in the
locomotion of preweanling rats

Collins, Zavala, Nazarian,

(Collins et al.,

1998;

& McDougall, 2000; Jackson &

2

Cooper,

1988; Leyton & Stewart,

Meier, & Crawford,

1992; McDougall, Garmsen,

1997; Ukai & Kameyama,

1985).

During early ontogeny the kappa opioid and dopamine

systems interact when modulating behavior. For example,

the kappa opioid-mediated locomotor activity of
preweanling rats can be attenuated by systemic

administration of a dopamine agonist

Meier, Bolanos,
al.,

1997,

Crawford,

(e.g., NPA)

& McDougall,

(Duke,

1997; McDougall et

1999; Nazarian, Rodarte-Freeman,

& McDougall,

1999). Moreover, microinjecting NPA into the dorsal
striatum is able to attenuate kappa opioid-induced

locomotor activity of young rats
Herbert, Marquez,

(Charntikov, Halladay,

& McDougall, 2008). Although the output

structures involved in this behavior have been determined,
the input pathways responsible for this kappa

opioid/dopamine interaction have not been identified.
Thus, the purpose of this thesis is to further investigate

how dopaminergic input pathways regulate the kappa
opioid-mediated locomotor activity of preweanling rats.
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CHAPTER TWO

KAPPA OPIOID RECEPTORS

Introduction

Opioid receptors are seven transmembrane G-protein
coupled receptors originally discovered in the early 1970s
using radioligand binding techniques

Simon, Hiller,

(Pert & Snyder,

& Edelman, 1973; Terenius,

1973;

1973). These

early studies demonstrated that endogenous opioid peptides
and opiates,

such as morphine, act as ligands at opioid

receptors and exert specific pharmacological and
physiological effects. The pharmacological activity of
these receptors, in particular the inability of nalorphine

to antagonize various narcotic analgetics in a uniform

manner, indicated the presence of receptor subtypes
(Gilbert & Martin,

& Gilbert,

1976; Martin, Eades, Thompson, Huppler,

1976). Based on different pharmacological

actions of various ligands

(morphine,

ketocyclazocine,

and

enkephalin), three types of opioid receptors were proposed

to exist - mu,

kappa, and delta. Thereafter, molecular

cloning of mu, kappa,
completed

and delta receptors has been

(Chen, Mestek, Liu, Hurley,

Keith, Morrison, Magendzo,

Mori, Nishi,

& Edwards,

& Yu,

1993; Evans,

1992; Fukuda, Kato,

& Takeshima, 1993; Kieffer, Befort,

4

1

Gaveriaux-Ruff,
al.,

& Hirth, 1992; Li et al.,

1993; Meng et

1993; Nishi, Takeshima, Fukuda, Kato,

In addition,

other opioid receptors

(X,

e,

and orphan)

have been identified and cloned (Marchese et al.,
Mollereau et al.,

1994; Wang et al.,

1993).

& Mori,

1994;

1994).

Based on hydrophobicity studies of opioid receptors,

it has been established that opioid receptors are composed

of seven transmembrane domains: a typical attribute of the
G-protein coupled receptor family. Amino acid sequences of
three cloned rodent opioid receptors are approximately 65%

identical and exhibit significantly more similarities in
the transmembrane regions than elsewhere (Reisine & Bell,
1993). This category of G-protein coupled receptors

functions by activation or blockade of effector systems
such as adenylyl cyclase, Ca2+ channels, K+ channels, or

phosphoinositol turnover (Chen et al.,. 1993; Cox,

North,

1993; Reisine & Bell,

& Reisine,

1993; Tallent,

1993;

Dichter, Bell,

1994; Yasuda et al., 1992). In addition,

kappa

opioid receptors localized in brain are able to influence

N-type calcium currents, thus altering the ability of
kappa agonists and dynorphin A to presynaptically inhibit

neurotransmitter release

(Gross & Macdonald,

1993).
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1987; North,

Kappa Opioid Receptor Subtypes
Kappa opioid receptors were originally discovered
utilizing in vivo pharmacological techniques

al.,

(Martin et

1976). Cloning of kappa opioid receptors revealed

their high affinity for exogenous and endogenous compounds

such as dynorphin A, U50488, U69593, but not to the mu

selective agonist DAMGO (D-Ala2, N-MePhea,
Gly-olS-enkephalin)

or the delta selective agonist DPDPE

(D-Pen2, D-PenS-enkephalin)

1982; Fischli, Goldstein, Hunkapiller,

& Morris,
subtypes -

Tempel,

1982;

& Hood,

Goldstein, Tachibana, Lowney, Hunkapiller,
Kawasaki et al.,

& Goldstein,

James,

(Chavkin,

& Hood,

1993; Lemaire, Chouinard,

Denis,

1979;
Panico,

1982). Kappa opioid receptors have at least two
ki

and

(Zukin, Eghbali, Olive,

k2

Unterwald,

&

1988). Kappa opioid ligands such as dynorphin A,

U50488, bremzocine, thylketocyclazocine, and tifluadom
bind to both Ki and
selectively to

ki

k2

sites, while U69593 binds

sites and not to

k2

sites

1988). At present, there are no selective

(Zukin et al.,
k2.

receptor

ligands. Moreover, a third kappa binding site

(K3) has

been proposed and is characterized by high affinity to

naloxone benoylhydrazone and low affinity for U50488
(Clark et al.,

1989).
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Kappa Opioid Receptor Localization
Kappa opioid receptor localization studies have been
performed using standard autoradiographic techniques

(Mansour, Khachaturian,
Rajpara, O'Connor,

Lewis, Akil,

& Watson, 1987; Nock,

1988; Quirion,

& Cicero,

Pilapil,

&

Magnan, 1987). These studies utilize radiolabeled ligands

to visualize kappa opioid receptors in brain slices.
Results of these studies revealed that kappa opioid

receptor populations are concentrated Tn the following

areas of the brain: striatum, nucleus accumbens,

superior

colliculus, substantia nigra, and cerebral cortex.

Localization of kappa.opioid receptors in rat, mouse,

and

guinea pig brain has also been studied using in situ
hybridization histochemistry (DePaoli, Hurley, Yasada,

Reisine,

& Bell,

1994; Mansour, Fox, Meng, Akil,

1994; Minami et al.,

1993; Xie et al.,

1994).

& Watson,

In rat

brain, the distribution of kappa opioid receptor mRNA is

high in the telencephalic regions of the brain, especially
in the medial striatum and nucleus accumbens, with the

exception of the globus pallidus where relatively low
levels of kappa opioid receptor mRNAs were detected. In
comparison, kappa opioid receptor mRNA varies from low to
moderate levels in the septal nucleus, while cortical

regions show intense signals in the VI layer of the

7

parietal,

temporal,

and occipital cortices. There are also

high levels of kappa opioid receptor mRNA in amygdaloid

nuclei.
In the rat diencephalon,

kappa opioid receptor mRNA

is dense in the paraventricular and supraoptic

(Leander, Zerbe,

hypothalamic nuclei

& Hart,

1985).

Furthermore, high concentrations of kappa opioid receptor
mRNA have been detected in the dorsomedial and
ventromedial hypothalamic nuclei

(Olson, Olson,

& Kastin,

1992). Mesencephalic regions of the rat brain express high
levels of kappa opioid receptor mRNA in the substantia
nigra and ventral tegmental area
Taylor, Watson,

Lewis, Akil,

& Akil,

(Mansour,

Hoversten,

1995; Mansour, Khachaturian,

& Watson,. 1988; McLean,

Rothman,

& Herkenham,

1986). These brain regions give rise to dopaminergic
pathways that project to the striatum,

globus pallidus,

nucleus accumbens, amygdala, and cerebral cortex (Le Moine

& Bloch,

1995; Le Moine et al.,

Portoghese,

Takemori,

& Cox,

1990; Werling,

1988).

Frattali,

Finally, moderate

levels of kappa opioid receptor mRNA have been found in

the superior and inferior colluculi

Lipkowski,

& Herz,

1989).
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(Millan, Czlonkowski,

Kappa Opioid Receptor Ligands
Two families of ligands interact with opioid

receptors: alkaloids and peptides

Janecka, Fichna,

(for a review,

see

& Janecki, 2004). Morphine is the oldest

known alkaloid agonist, a compound which is derived from

poppy seeds

(Gulland & Robinson,

1923). Morphine and other

alkaloid opiate agonists are commonly used to induce

analgesia. In pharmacological studies, alkaloid agonists,
and morphine specifically, are ligands that target mu
opioid receptors with much higher affinity than delta or
kappa opioid receptors

(Takemori & Portoghese,

1987).

Alkaloid antagonists include naloxone and naltrexone

(Blumberg & Dayton,

1974). While both of these opioid

antagonists are nonselective (i.e., they target all three

opioid receptors) they have much higher affinity for the
mu receptor

(Magnan,

1982). Consequently,

Paterson, Tavani, & Kosterlitz,
for a ligand to be characterized as

an opioid agonist its agonistic actions have to be

"naloxone-reversible" (Leslie,

1987).

Peptide opioid receptor ligands have been divided

into two categories - typical and atypical

(Teschemacher,

1993). The typical opioid peptide receptor ligands include
enkephalins, [3-endorphin,

and dynorphins. These ligands

vary in their affinity for the three main opioid receptors
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and all exhibit nonspecific properties by binding to more

than one receptor type. In particular,

[Met]- and

[Leu]-enkephalin express much higher affinity for delta
receptors than for kappa or mu receptors

(Mansour et al.,

1995; Mulder, Wardeh, Hogenboom,

& Frankhuyzen,

Schoffelmeer, Warden, Hogenboom,

& Mulder,

1989;

1991).

p-Endorphin binds with equal affinity to both mu and delta
opioid receptors, while binding with much lesser affinity

to the kappa receptor

(Hollt, Sanchez-Blazquez,

& Garzon,

1985). Furthermore, dynorphin A and B bind with high
affinity to the kappa receptor and with lower affinity to

mu and delta opioid receptors. The atypical opioid peptide
ligands derive from various protein sources,

blood protein, hemoglobin,

and even amphibian skin

(Brantl, Teschemacher, Henschen,
Lazarus, Bryant, Cooper,
de Castiglione,
Sanderson,

such as milk,

& Lottspeich,

& Salvadori,

Piani, Gozzini,

1979;

1999; Montecucchi,

& Erspamer,

1981; Nyberg,

& Glamsta, 1997).

Kappa opioid receptor ligands can be divided into two

categories: agonists and antagonists. Kappa opioid

agonists are derived from the heptadecapeptide dynorphin A
family of putative endogenous ligands for kappa opioid

receptors

(Chavkin et al.,

1982). These ligands are

nonselective agonists and bind to mu and delta receptors

10

with high affinity. At present, there is a limited pool of
kappa opioid ligands with antagonistic properties
et al.,

Aldrich,

1988; Lemaire & Turcotte,

(Gairin

1986; Wan, Murray,

&

1999). Among the notable nonpeptide kappa opioid

antagonists are nor-binaltorphimine,

5'-guanidinonaltrindole
Murray,

(GNTI), and dynantin (Bennett,

& Aldrich, 2002; Jones, Hjorth, Schwartz,

Portoghese,

&

1998; Larson, Jones, Hjorth, Schwartz,

Portoghese, 2000; Lin, Takemori,

& Portoghese,

&

1993; Lu et

al., 2001). These ligands exhibit both high selectivity
and high affinity for kappa opioid receptors. Notably,
dynantin is a relatively new and potent kappa opioid

antagonist with subnanomolar kappa antagonistic potency

(Lu et al., 2001) .

Ontogeny of Kappa Opioid Receptors

The presence of kappa opioid receptors can be
detected as early as the 14th day of gestation in both

mouse and rat brain (Kent,
Barg, Bern, Coscia,

& Loh,

Pert,

& Herkenham,

1981; Rius,

1991). A number of studies have

investigated the ontogenesis of kappa opioid receptors and
have reported somewhat consistent results
& Viveros,

(Kitchen,

1990; Petrillo, Tavani, Verotta, Robson,

Kelly,
&

Kosterlitz, 1987; Volterra, Brunello, Restani, Galli,

11

&

1986). Specifically, it has been shown that the

Racagni,

number of kappa opioid receptors in neonatal rats
as revealed through Scatchard analysis,

those of adults

(Kitchen et al.,

(PD 4),

is comparable to
further

1990). However,

analysis revealed that the number of kappa opioid
receptors is significantly higher (approximately 7-fold

increase) on PD 10 in comparison to PD 5

(Kitchen et al.,

1990). Kappa opioid receptor numbers remain consistently

high until PD 20 after which a gradual decline is
apparent,

al.,

reaching adult like numbers on PD 30

(Kitchen et

1990). The time-course of these quantitative changes

is comparable for both

(Petrillo et al.,
Tavani, Robson,

ki

and

k2.

opioid receptors

1987; Spain, Roth,

& Kosterlitz,

& Coscia,

1985;

1985).

Localization studies have shown that by late

gestation the pattern of kappa opioid receptor
distribution is comparable to that of adults
Pintar,

1998).

In particular,

(Zhu,

Hsu,

&

studies utilizing in situ

hybridization have confirmed that kappa opioid receptors

are present in rodent basal ganglia, thalamus,
hypothalamus,

raphe,

and the ventral tegmental area during

the mid- and late-gestation period (Zhu et al.,

1998).

Radioligand binding studies have reported similar results,

with high densities of both

kx

12

and

k2

opioid receptors

being present in the striatum, nucleus accumbens,

olfactory tubercle, amygdala,
and ventral tegmental area
1987; Unterwald,

Knapp,

substantia nigra, midbrain,
& Leslie,

(Kornblum, Hurlbut,

& Zukin, 1991).

Endogenous and exogenous opioid ligands are capable

of affecting cell growth and functioning of the developing
central nervous system (Crofford & Smith,

Gray,

& Pilar,

Whitmore,

1985; Simon,

1980; Smith, Hui,

McLaughlin,

1977,

1971; Slotkin,
& Crofford,

1973; Meriney,

&

Seidler,

1977; Zagon &

In fact, the endogenous

1983).

neurotransmitter is necessary for the appropriate
development of various receptor types

Stiene-Martin, Mattson,

McLaughlin,

1983,

& Hauser,

(Mattson,

1988;

1993; Zagon &

1987). Specifically, the appearance of

peptides and opioid receptors has a close temporal

relation, thus indicating a functional role for opioid
ligands in opioid receptor development
1985; Zagon & McLaughlin,

(Meriney et al.,

1983). These findings suggest

that kappa opioid receptors are functional during the

prenatal period and continue to mature across neonatal
stages

(Herman & Panksepp,

1978; Jackson & Sewell,

Panksepp, Siviy, Normansell, White,

13

& Bishop,

1984;

1982).

CHAPTER THREE
DOPAMINE RECEPTORS

Introduction

Dopamine is a chemical compound which functions as a

neurotransmitter and as a neurohormone in a variety of

organisms. Dopamine is a member of the catecholamine
family that derives from the amino acid tyrosine and is
itself a precursor to norepinephrine and epinephrine

(Hess, Connamacher, Ozaki,

& Udenfriend,

Friedman, 1965; Levin, Levenberg,
Spector,

Sjoerdsma,

Udenfriend, 1964).

& Udenfriend,

1961; Kaufman &

& Kaufman,

1960; Levitt,

1965; Nagatsu, Levitt,

&

Synthesis of dopamine occurs in nervous

tissue and adrenal glands where the essential amino acid
tyrosine is converted to DOPA through enzymatic reactions
involving tyrosine hydroxylase.
converts DOPA to dopamine

2000).

DOPA decarboxylase then

(Kandel, Schwartz,

& Jessell,

In the central nervous system, dopamine cell bodies

are primarily located in the olfactory bulb,

substantia

nigra, ventral tegmental area, and hypothalamus

et al., 200.0; Montmayeur, Guiramand,
Snyder,

Roberts,

& Borrelli,

(Calabresi
1993;

& Sealfon, 1991). Three major

dopaminergic pathways originate from the substantia nigra
and the ventral tegmental area:
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1) the nigrostriatal

pathway, which is involved in motor control; 2)

the

mesolimbic pathway, which is involved in reward and

motivation; and 3) the mesocortical pathway, which is
involved in motivation and emotional processes.

Structure and Subtypes of Dopamine Receptors

Dopamine stimulates five dopamine receptor subtypes Di, D2, D3,

D4, and D5 (Seeman & Van Tol, 1994). These five

dopamine receptors can be categorized into two distinct

families: Dl - which includes the Di and D5 subtypes, and
D2 - which includes the D2,

D3, and D4 subtypes. These two

distinct families of dopamine receptors are classified
based on their molecular properties. All known dopamine

receptors are G-protein coupled receptors and their

activation can either stimulate or inhibit adenylyl
cyclase activity (Clark & White,

1987; Stoof & Kebabian,

1981). Dl receptor activation typically stimulates
adenylyl cyclase and results in an excitatory cellular

response,'while D2 receptor activation leads to an
inhibitory cellular response due to depression of adenylyl
cyclase activity (Clark & White,

1981). Specifically,

1987; Stoof & Kebabian,

activation of Dl receptors leads to

the disengagement of the G-protein from its original site
resulting in the stimulation of adenylyl cyclase and, as a
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consequence,

increased levels of the second messenger

cyclic adenosine monophosphate (cAMP). Elevated levels of

cAMP usually cause an excitatory response in the cell.

Conversely,

stimulation of the D2 family of dopamine

receptors (D2,

D3, and D4) attenuates cellular

responsiveness, because activation of an inhibitory

G-protein leads to elevated levels of phosphodiesterase

which breaks down cAMP (Clark & White,
Kebabian,

1987; Stoof &

1981) .

Distribution of Dopamine Receptors
Dopamine receptor localization studies employ various

neurochemical techniques,

including autoradiography and

mRNA isolation. Autoradiographic studies provide
compelling evidence for the regional distribution of

dopamine receptors in the central nervous system. In

particular, both DI and D2 receptors are present in the
striatum and nucleus accumbens of mammalian brain

(Baldessarini & Tarazi,
& Baldessarini,

1996; Tarazi, Campbell, Yeghiayan,

1998). Furthermore, radioligand binding

studies have been able to localize dopamine receptors on

pre- and postsynaptic elements.

Specifically, DI and D2

receptors are predominantly located on postsynaptic
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neurons within the striatum and nucleus accumbens

et al.,

(Tarazi

1998).

Di dopamine receptors are the most common subtype
among the dopamine family (Dearry et al.,

al.,

1990; Fremeau et

1991) . Di receptor mRNA has been found in the

striatum, nucleus accumbens, and olfactory tubercle
(Gerfen et al.,

1990; Le Moine, Normand,

& Bloch,

1991).

Dx receptors are also present in the substantia nigra pars

reticulata and entopeduncular nucleus,

even though no Di

receptor mRNA has been found in these structures

et al.,

1990; Fremeau et al.,

1991; Gerfen & Engber,

1991; Weiner et al.,

Le Moine et al.,

(Dearry
1992;

1991). This

discrepancy is due to the absence of dopamine cell bodies
in the substantia nigra pars reticulata and entopeduncular
nucleus and the presence of neuronal projections

containing Di receptors. In fact,

a number of studies have

traced Dx bearing projections to striatal GABAergic
neurons that coexpress substance P

Le Moine et al.,

(Gerfen & Engber,

1992;

1991).

D5 receptors,

in comparison to Di receptors, exist in

significantly smaller populations and are mainly found in
the hippocampus, lateral mamillary nucleus, and the
parafascicular nucleus of the thalamus

al.,

1992; Tiberi et al.,

(Meador-Woodruff et

1991). In addition to these
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structures,

D5 receptor mRNA is found in the striatum,

substantia nigra, hippocampus, thalamus,

cortex (Huntley, Morrison, Prikhozhan,

and cerebral

& Sealfon,

Rappaport, Sealfon, Prikhozhan, Huntley,

1992;

& Morrison,

1993).
Di and D5 receptors are frequently colocalized on
pyramidal neurons located in the prefrontal, premotor,

entorhinal, and cingulate cortices. Both Di and D5

receptors occur pre- and postsynaptically, with
postsynaptic localization being more prevalent

al., 1992; Levey et al.,

(Huang et

1993). Within individual

pyramidal neurons, Dx receptors tend to be located on
dendritic spines, while D5 receptors are primarily

localized on dendritic shafts
Smiley, Levey, Ciliax,

(Bergson et al.,

& Goldman-Rakic,

1995;

1994). Although

the pharmacological properties of Di and D5 receptors are

analogous their function partially depends on their
dendritic localization.

The D2 family of dopamine receptors are G-protein
coupled receptors that inhibit adenylyl cyclase activity.

The D2 receptor is predominantly located in the striatum,

olfactory tubercle, and nucleus accumbens core, where it
is expressed by neurons that co-release GABA and
enkephalin (Bouthenet et al.,
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1991; Le Moine & Bloch,

1995; Le Moine et al.,

1990) . D2 receptors- can also be

found in the shell of the nucleus accumbens, where they
are expressed by GABAergic neurons that co-release

neurotensin (Diaz et al.,

1994). Cell bodies of neurons

bearing D2 receptors have been traced to various cortical

(prefrontal, temporal, motor,

areas

somatosensory,

posterior parietal, and occipital), septal nuclei,
amygdala, and granule cells of the hippocampal formation

(Bouthenet et al.,

1991).

D2 receptor mRNA is also present

in dopaminergic neurons located in the hypothalamus,

substantia nigra pars compacta, and ventral tegmental area

(Bouthenet et al.,

1991; Weiner et al.,

1991).

Immunohistochemical analysis of D2 receptors reveals that

they are expressed by GABAergic medium spiny neurons of
the striatum, with D2 receptors being precisely positioned

in spiny dendrites and spiny heads

(Levey et al., 1993).

The D3 receptor is located in a number of limbic
areas,

such as the ventromedial thalamus shell of the

nucleus accumbens, olfactory tubercle, and islands of

Calleja (Bouthenet et al.,
Levesque et al.,

1992).

1991; Diaz et al.,

1994;

In addition, relatively low levels

of D3 receptors are detected in the hippocampus, septal

area, medial temporal lobe, and a number of cortical areas

(Bouthenet et al.,

1991). In comparison,
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D3 receptor mRNA

has been found in the substantia nigra pars compacta, the
ventral tegmental area, and the cerebellum

1994,

(Diaz et al.,

1995).

The D4 receptor is found in high levels in frontal
cortex, hippocampus, amygdala, hypothalamus, and the
mesencephalon

Tol et al.,

(O'Malley, Harmon, Tang,

1991). In contrast,

1991).

1992; Van

low levels of D4 receptor

mRNA are detected in the basal ganglia

1992; Van Tol et al.,

& Todd,

(O'Malley et al.,

Immunohistochemical analysis

of D4 receptors in the cerebral cortex and hippocampus
revealed that this receptor subtype is endogenous to

GABAergic interneurons, both pyramidal and nonpyramidal,
that modulate GABAergic transmission within those brain

regions

(Mrzljak et al.,

1996).

Colocalization of Dl and D2 Receptors

The striatum gives rise to two distinct populations
of GABAergic neurons that disproportionately contain Dl

and D2 dopamine receptors

(Bloch & Le Moine,

1994; Gerfen

& Keefe, 1994). GABAergic neurons projecting to the
substantia nigra and entopeduncular nucleus

(i.e.,

striatonigral neurons) predominantly express Dl receptors

and co-release substance P and dynorphin
1990; Yung et al.,

1995).

In contrast,
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(Gerfen et al.,

D2 receptors

preferentially occur on GABAergic neurons that project to

the globus pallidus

(i.e., striatopallidal neurons)

and

corelease enkephalin (Gerfen et al., 1990; Yung et al.,

1995). Although numerical assessment varies, most studies
agree that the majority of striatopallidal neurons express

both DI and D2 receptors, with D2 receptors predominating.
Striatonigral neurons exhibit the opposite

characteristics, because they possess both Dl and D2
receptors, with the majority of receptors being Dl (Aizman

et al., 2000; Deng, Lei,
1995b; Surmeier et al.,

Ariano,

& Reiner,

2006; Hersch et al.,

1992; Surmeier, Reiner, Levine,

&.

1993). These findings have been confirmed by

electrophysiological studies measuring Ca2+ and Na+

currents within striatal neurons
Levine,

1993; Surmeier et al.,

(Cepeda, Buchwald,

&

1992).

Dopamine Receptor Stimulation and
Dopamine Transmission

Neurons are capable of expressing dopamine receptors
on both pre- and postsynaptic elements. On nigrostriatal

dopamine terminals, presynaptic D2 receptors are called

autoreceptors because of their ability to regulate the
synthesis and release of dopamine from the terminal.
Stimulation of synthesis-modulating D2 autoreceptors, via

dopamine agonists or endogenous dopamine,
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activates a

second messenger system that decreases dopamine synthesis

(Stoof & Kebabian,

1984; Surmeier et al.,

1992).

Release-modulating D2 autoreceptors, on the other hand,
alter dopamine release by regulating Ca2+ and K+

conductance

North,

(Bigornia et al.,

1990; Lacey, Mercuri,

&

1987). Blockade of D2 autoreceptors either

increases dopamine synthesis or release depending on the
type of autoreceptor affected (Hakansson et al., 2004;
Stoof & Kebabian, 1984).
Activation of postsynaptic D2 receptors depresses

adenylyl cyclase activity and results in an inhibitory

response (Clark & White,

1987; Stoof & Kebabian,

1981).

Stimulation of postsynaptic D2 receptors, which

predominate on striatal medium spiny neurons projecting to
the globus pallidus, causes inhibitory postsynaptic

potentials in the distal neurons

(Mottola et al., 2002).

Stimulation of postsynaptic Dl receptors, which are

predominantly located on striatal neurons projecting to

the substantia nigra and endopeduncular nucleus, typically

increases adenylyl cyclase activity and results in
excitatory postsynaptic potentials (Pereda, Triller, Korn,
& Faber,

1992; Seamans, Durstewitz, Christie,

Sejnowski,

Stevens,

&

2001). In summary, dopamine exerts an

inhibitory effect by stimulating postsynaptic D2 receptors
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located on striatopallidal neurons

(which comprise the

indirect pathway); whereas, dopamine has an excitatory
effect by stimulating postsynaptic DI receptors located on
striatonigral neurons

(which comprise the direct pathway) .

Ontogeny of Dopamine Receptors
Dopamine neurons start developing at embryonic day

12, with the initial topographical epicenter being the
midbrain and medial forebrain bundle
Torres,

(Gates, Coupe,

Fricker-Gates, & Dunnett, 2004; Nakamura,

Shirasaki,

& Murakami, 2000; Smidt & Burbach,

Ito,

2007).

Dopamine neurons originating from the substantia nigra and
ventral tegmental area complete striatal innervation

around embryonic day 19 and cortical innervation by the

end of the first postnatal week (Kalsbeek, Voorn, Buijs,
Pool,

& Uylings,

Van Eden et al.,
Groenewegen,

1988; Specht,

Pickel,

Joh,

& Reis,

1981;

1987; Voorn, Kalsbeek, Jorritsma-Byham,

&

1988). Dopamine can be detected in the rat

embryo as early as the second half of the gestation period
(Golden,

1973; Lauder & Bloom,

1974).

Studies examining DI receptor development in striatal

regions have reported contradictory results ranging from:
a) a gradual increase of Dl receptors from birth to

adulthood; b)

a gradual increase of Dl receptors from
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birth to postnatal days 35-40,

decrease of receptors

followed by a gradual

(pruning) into adulthood; to c) no

age-dependent changes in receptor numbers

Bennett, 1990; Gelbard, Teicher, Faedda,
1989; Giorgi et al.,

Hyttel,

& Murrin,

(Broaddus &

& Baldessarini,

1987; Murrin & Zeng, 1990;

Zeng,

1988). Although there is a lack of

consensus about prenatal and postnatal development of DI
receptors, there is agreement about the modulators of that
development. A number of studies have confirmed that

receptor stimulation during development is necessary for

the proper maturation of the system. Support for this
hypothesis is two- fold: a)

normal development of Dl

receptors is disrupted by removal of endogenous dopamine
using 6-hydroxydopamine,

and b) normal postnatal

development of Dl receptors, following 6-hydroxydopamine

treatment, is reinstated by administration of the Dl
agonist SKF38393

Gelbard et al.,

1991). Thus,

(Frohna, Neal-Beliveau,

1990; Neal & Joyce,

& Joyce,

1995;

1992; Teicher et al.,

stimulation of Dl receptors via either

endogenous or exogenous ligands is sufficient and

necessary for their normal development.
Studies examining D2 receptor proliferation during

prenatal and postnatal stages typically focus on the
striatal complex in the rat. Using the in situ
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hybridization technique of localizing mRNA signals in

developing rat brain, it has been shown that D2 dopamine
receptor mRNA can be detected in the prenatal striatum as
early as gestation day 14 with further proliferation

peaking at PD 16,

adulthood

followed by a slight decline into

(Chen & Weiss,

1991). However, a more precise

estimation of D2 dopamine receptors, employing receptor

autoradiography, shows a gradual increase from low levels
at birth to adult levels by PD 30
Hartley & Seeman,

(Chen & Weiss,

1983; Pardo, Creese, Burt,

1977; Rao, Molinoff,

& Joyce,

1994). Unlike DI receptors,

1991;

& Snyder,

1991; Schambra et al.,

D2 receptors seem to

proliferate independent of endogenous dopaminergic

stimulation, although development of 02 receptors can be
impaired by spiperone

(a D2 receptor antagonist)

administed from birth to postnatal day 32
1987; Kostrzewa & Saleh,

(Breese et al.,

1989; Neal & Joyce,

1992; Thomas,

Neal-Beliveau, & Joyce, 1998).
The dopamine system is a complex and important

mediator of a variety of neurochemical and physiological

mechanisms. Understanding the processes underlying the
development of the dopamine system can elucidate a number

of pathologies involving neural networks. Efforts have

been made to explicate the ontogeny of the dopamine
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system, including the development and functioning of
receptors, the role of endogenous and exogenous ligands,
and the extent of neuronal proliferation. Although studies

have occasionally yielded inconsistent results, it is

clear that the dopamine system develops rapidly during
early ontogeny and continues to mature across the
preweanling period.
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CHAPTER FOUR

BASAL GANGLIA

Introduction

The basal ganglia is a group of nuclei found in the

telencephalon, diencephalon,

and midbrain which are

interconnected through a set of networks with the cerebral
■cortex, thalamus, and brain stem (see Figure 1)

(Hauber,

1998; Mello & Villares, 1997). It is thought that the
basal ganglia evolved from a relatively simple motor

structure to a complex system that is not only responsible
for a variety of motor behaviors but also plays a cardinal
role in cognition, learning, reward, and motivation
(Albin, Young, & Penney,

& Kimura,

1989; Graybiel, Aosaki,

Flaherty,

1994; Kimura, 1995; Knowlton, Mangels,

& Squire,

1996; Schultz, 1994). The basal ganglia is composed of a
group of structures interconnected through a series of

reciprocal regulatory pathways. Anatomical structures
comprising the basal ganglia vary from species to species,

but typically consist of the striatum (caudate and

putamen), globus pallidus, subthalamic nucleus,
entopeduncular nucleus, and' the substantia nigra

1998; McGeorge & Faull,

(Hauber,

1989; Parent & Hazrati, 1994). The

striatum is a critical relay station that mainly receives
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The striatonigral (direct) pathway projects from the caudate-putamen to the substantia nigra
;pars reticulata and entopeduncular nucleus. The striatopallidal (indirect) pathway projects from
the caudate-putamen and carries signals via GABAergic connections to the globus pallidus
and, subsequently, to the substantia nigra pars reticulata and entopeduncular nucleus by way
of the subthalamic nucleus. GP, globus pallidus; SU, subthalamic nucleus; EN,
entopeduncular nucleus; SNPR, substantia nigra pars reticulata; SNPC, substantia nigra pars
compacta; DA, dopamine; ACh, acetylcholine; Glu, glutamate; S.P., substance P. Partially
adapted from Hauber (1998).

Figure 1. The Circuitry of the Basal Ganglia

input from the cerebral cortex. This input is further
relayed, via the direct and indirect pathways, to the

major processing and output areas. Processing'areas,
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such

as the globus pallidus and subthalamic nucleus, receive
signals from the striatum and redistribute them to the
major basal ganglia output areas - entopeduncular nucleus

and substantia nigra pars reticulata (see Figure 1).

In

turn, the substantia nigra pars compacta provides

dopaminergic innervation to the striatum, globus pallidus,
and subthalamic nucleus. Output from the entopeduncular
nucleus and substantia nigra pars reticulata is

distributed to major motor areas, such as motor nuclei of
the brainstem, via the thalamus and cortical motor areas.

Striatum

The striatum (caudate-putamen)

is a chief component

of basal ganglia circuitry due to the fact that it relays

signals received from the cerebral cortex to major
processing (globus pallidus and subthalamic nucleus)
output structures of the basal ganglia

and

(substantia nigra

pars reticulata and entopeduncular nucleus) via the
striatonigral

pathways

(direct)

and striatopallidal

(Bolam, Hanley, Booth,

Hakansson, Borgkvist,

(indirect)

& Bevan, 2000; Fisone,

& Santini, 2007; Hauber,

1998). The

striatonigral pathway is composed predominantly of Dl

bearing neurons

(D2 receptors are coexpressed in lower

concentrations)

that originate in the striatum and project
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to the substantia nigra pars compacta along with the

entopeduncular nucleus. These striatonigral neurons
corelease GABA, substance P, and dynorphin

(Gerfen,

1992).

In addition, the striatum connects with the globus

pallidus via neurons that corelease GABA and enkephalin

(Fink et al.,

1992; Gerfen, 1992; Schiffmann,

Jacobs,

&

Vanderhaeghen, 1991). These striatopallidal neurons
express D2 receptors

lower concentrations)

(Dl receptors are coexpressed in
and form the initial part of the

indirect pathway, which further extends to the substantia
nigra pars reticulata and the entopeduncular nucleus by
way of the subthalamic nucleus

(Hauber, 1998). Although

the direct pathway is activated by Dl receptor stimulation
and the indirect pathway is inhibited by D2 receptor

stimulation, there is a small degree of colocalization of
these receptors on neurons forming either pathway (Aizman
et al., 2000; Deng et al., 2006; Hersch et al.,

Surmeier et al.,

1995b;

1992, 1993).

The functioning of striatal neurons is affected by a

number of neurotransmitters and modulators. For instance,
the neuronal activity of Dl expressing neurons can be

regulated pre- and postsynaptically via dynorphin, while
the functional properties of the dopamine receptor can be
affected by the neuromodulator adenosine
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(Ferre et al.,

1996; Steiner & Gerfen,

1996).

In comparison,

D2

expressing neurons of the indirect pathway can be
modulated by stimulating adenosine A2a receptors in the

striatum (Ferre, O'Connor,

Fuxe,

& Ungerstedt,

1993;

Ferre

et al., 1996). Activity of both the direct and indirect
pathways is also affected by serotonergic inputs from the
dorsal nucleus of the raphe and caudal linear nucleus

(Imai, Steindler,
& Watkins,

& Kitai,

1989; Vertes,

1986; Soghomonian, Descarries,

1991). Finally, it is important

to note that the striatal neurons forming the direct and
indirect pathway can be influenced by small intrinsic

interneurons releasing acetylcholine (Di Chiara, Morelli,

& Consolo,

1994).

Globus Pallidus

The globus pallidus is part of a signal processing
network in the core of the basal ganglia. Major input to

the globus pallidus is provided via striatal GABA and
enkephalin releasing neurons making up the indirect

pathway.

In addition to these striatopallidal corrections,

the globus pallidus receives glutamatergic input from the

thalamus and subthalamic nucleus

(Feger,

1997). Dopamine

receptors are also present in the globus pallidus
(Richfield, Young,

& Penney,

1987)
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and are activated by

dopamine released from neurons projecting from the
substantia nigra pars compacts

(Lindvall & Bjorklund,

1979) . The globus pallidus sends signals to most basal
ganglia structures via GABAergic outputs. The subthalamic

nucleus, substantia nigra pars reticulata, and the

entopeduncular nucleus are among those brain areas
influenced by the globus pallidus through its inhibitory

transmission

(Carter & Pycock,

1982; DeVito, Anderson,

1978; DeVito & Anderson,

& Walsh,

1980; Parent & Hazrati,

1995). In addition to the GABAergic outputs, the globus

pallidus gives rise to cholinergic neurons that project to

the cortex (Heimer, Zahm,

& Alheid,

1995). Overall, the

globus pallidus is in a unique position to control a wide
variety of basal ganglia functions because of its
(a) direct connections to the substantia nigra pars

compacta and the entopeduncular nucleus,

(b)

indirect

projections to proximal areas via the subthalamic nucleus,

and (c)

its inhibitory connections with thalamic nuclei.

Subthalamic Nucleus
The subthalamic nucleus receives most of its incoming
projections in the form of glutamatergic input
Kita, 1993)

from pyramidal cell collaterals

(Fujimoto &

(Ryan & Clark,

1991). These pyramidal cells primarily project from
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frontal areas of the cerebral cortex
Shammah-Lagnado,

Silva, & Ricardo,

(Canteras,

1990). Additional input

to the subthalamic nucleus comes in the form of inhibitory
GABAergic signals from the globus pallidus

(Feger,

1981)

and dopaminergic signals from the substantia nigra pars

compacta (Hassani, Francois, Yelnik,

& Feger,

1997) .

Output from the subthalamic nucleus is predominantly
excitatory in nature and is mediated by glutamatergic

neurons. The subthalamic nucleus uses this excitatory
output to communicate with the globus pallidus,

substantia

nigra pars reticulata, and entopeduncular nucleus. Many of

these outputs originate from the same population of
neurons and further collateralize to different locales

(Deniau, Hammond, Riszk,

& Feger,

1978). Thus, the

subthalamic nucleus is structurally and functionally

situated to modulate basal ganglia functioning through
signal processing and relaying signals between input and

output areas.

Substantia Nigra Pars Reticulata
The substantia nigra pars reticulata is one of two

basal ganglia output structures

(the other being the

entopeduncular nucleus). It plays an important role in
controlling motor related behavior because of its
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GABAergic connections with various premotor structures,
including the thalamus,

superior colliculus,

and the

pedunculopontine tegmental nucleus

(Deniau & Chevalier,

1992; Gerfen, Staines, Arbuthnott,

& Fibiger,

Kitai,

1987; Nakanishi, Kita,

& Kitai,

1982; Kita &

1987). The two

major inputs to the substantia nigra pars reticulata are

the striatonigral (direct)

and the striatopallidal

(indirect) pathways. As previously mentioned, neurons
comprising the striatonigral pathway originate in the

caudate-putamen and corelease GABA, dynorphin, and
substance P (Chevalier & Deniau,

1990) . In contrast, GABA

neurons of the striatopallidal pathway corelease
enkephalin (Fink et al.,

1992; Schiffmann et al.,

1991).

The striatopallidal pathway projects from the

striatum to the substantia nigra pars reticulata by way of

the globus pallidus and subthalamic nucleus. Specifically,
the substantia nigra pars reticulata is modulated by

excitatory glutamatergic inputs from the subthalamic
nucleus

(Hammond, Deniau, Rizk,

et al.,

1987)

& Feger,

1978; Nakanishi

and inhibitory GABAergic inputs from the

globus pallidus

(Smith & Bolam,

1989) . GABAergic inputs

from the direct and indirect pathways converge on one site
in the substantia nigra pars reticulata
Ingham, von Krosigk,

& Smith,
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(Bolam, Smith,

1993), thus allowing for an

integration of inputs from the two parallel pathways. The

substantia nigra pars reticulata, in turn,

serves as one

of the chief output structures of the basal ganglia,

modulating various premotor nuclei via its GABAergic

outputs. Moreover,

its strategic location at the point of

convergence of the two major pathways makes the substantia
nigra pars reticulata a critical component involved in the
information processing and signal discrimination of the

basal ganglia.

Entopeduncular Nucleus
The entopeduncular nucleus,

also referred to as the

internal segment of the globus pallidus,

is an important

output structure of the basal ganglia and functions in
much the same way as the substantia nigra pars reticulata.

For example, the globus pallidus inhibits the

entopeduncular nucleus via GABAergic transmission (Fonnum,
Gottesfeld,
Fibiger,

& Grofova,

1978; Nagy, Carter, Lehmann,

&

1978), while the subthalamic nucleus stimulates

the entopeduncular nucleus through glutamatergic
connections

(Nakanishi et al.,

1987). Dopaminergic input

to the entopeduncular nucleus is provided by the

substantia nigra pars compacta (Lindvall & Bjorklund,

1979). As a major output system, GABAergic fibers from the
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entopeduncular nucleus project throughout the forebrain.
This GABAergic activity provides inhibitory signals to

several important motor structures, including the thalamus
(Carter & Fibiger,

pedunculopontine nucleus
Ikai,

al.,

& Mizuno,

1981),

1978; van der Kooy & Carter,
(Nauta,

1979; Takada, Tokuno,

1994), and superior colliculus

(Takada et

1994). Therefore, the entopeduncular nucleus is a

critical component of the basal ganglia, acting as an
output structure that distributes an inhibitory signal to

a number of important motor areas.

Substantia Nigra Pars Compacta

The substantia nigra pars compacta supplies

dopaminergic modulation to the major input

and

(striatum)

processing (globus pallidus and subthalamic nucleus)

areas

of the basal ganglia. These dopamine neurons coexpress

cholecystokinin and neurotensin (Seroogy et al., 1988),
which may serve as modulators for several feedback loops

carrying GABAergic signals via the direct and indirect

pathways
al.,

(Fuxe et al.,

1995; O'Connor, 2001; Tanganelli et

1993). The presence of NMDA and nonNMDA glutamate

receptors in the substantia nigra pars compacta
1993)

(Kalivas,

indicates possible excitatory input from the

prefrontal cortex and subthalamic nucleus. This
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glutamatergic input probably regulates the firing rates of
dopamine neurons in the substantia nigra pars compacta and

may be part of a feedback system. Hence, the substantia
nigra pars compacta is in position to control the

functioning of major input and processing structures of

the basal ganglia via dopaminergic modulation of the
direct and indirect pathways.

Summary
The basal ganglia is a massive brain network that is

involved in receiving incoming information from the

cerebral cortex, distributing that signal to specialized
processing structures, and providing output signals to
subcortical and cortical areas. The basal ganglia employs

an intricate array of pathways and feedback networks
ensuring accurate signal processing. Both inhibitory and
excitatory signals are utilized by the basal ganglia.

For

instance, glutamatergic and GABAergic neurons are found
throughout the indirect pathway, while GABA is the primary
neurotransmitter of the direct pathway. The interaction of
these systems creates a complex environment where

excitation, inhibition, and disinhibition are used to
modulate behavioral processes. In summary, the basal'
ganglia is a complex set of structures, with a number of
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ganglia-thalamocortical loops which employ redundant
feedback systems and competitive networks, that are
involved in information processing related to motor,
cognitive, and emotional processes.
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CHAPTER FIVE
DOPAMINE MEDIATED BEHAVIOR

Introduction

Dopamine modulates a variety of behaviors including,

but not limited to, learning, motivation and reward,
cognition,

and motoric function. Dopamine modulates

behavior by altering an intricate array of mechanisms,

such as varying the intensity of dopaminergic tone,
stimulating various dopamine receptor subtypes, affecting

pre- and postsynaptic receptors,

and by synergistically

activating opposing dopaminergic networks. Exogenous
agonism and antagonism has been used to elucidate the role

of dopaminergic systems for behavioral functioning.
Administration of pharmacoagents varies from systemic

treatment to' precisely targeted intracranial injections.
In addition, brain lesioning techniques are employed in
combination with pharmacological testing to reveal the

functional properties of dopamine systems.

Systemic Administration of Dopamine Agonists
Selective Dl and D2 receptor agonists differentially
affect the unlearned behaviors of adult rats and mice.

Systemic administration of the selective Dl agonist
SKF38393 to normosensitive rats does not produce robust
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locomotor activity nor is it capable of inducing
stereotyped behaviors, although low levels of locomotion

are sometimes reported (Arnt, 1985; Molloy & Waddington,
1984; Neisewander, Lucki,

& McGonigle, 1991). However,

animals depleted of monoamines

(i.e.,

reserpinized rats)

or 6-OHDA-treated rats exhibit elevated levels of
locomotion following systemic SKF38393 treatment

& Mueller, 1985;

1985; Breese, Baumeister, Napier, Frye,
Breese et al.,

(Arnt,

1987; Neisewander et al.,

1991). The

'enhanced locomotor activity of reserpine-treated rats can

be blocked by either systemic administration of a

selective Dl antagonist
(haloperidol)

antagonist

(SCH23390)

or a nonselective Dl/D'2

(Starr, Starr,

1987; Zarrindast & Eliassi,

& Kilpatrick,

1991; Zarrindast & Minaian,

1991).

Systemic administration of selective D2 agonists,
such as quinpirole or pergolide, affects motor behavior of

rodents in a biphasic manner (Bradbury, Cannon, Costall,
Naylor,

1984; Costall, Lim,

& Naylor,

1981; Eilam &

Szechtman, 1989; Frantz & Van Hartesveldt,

Herbster,

1995; Koller &

1988). Low doses of quinpirole attenuate

locomotor activity, while high doses of this D2 agonist
augment locomotion (Eilam & Szechtman,

Hartesveldt,

1989;

1995; Van Hartesveldt, Meyer,
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Frantz & Van

& Potter,

&

1994). This disparity in behavioral responsiveness can be

explained by the selective affinity of pre- and
postsynaptic D2 receptors. Specifically, presynaptic D2
receptors exhibit a higher affinity for quinpirole than
postsynaptic D2 receptors. Therefore,

at lower doses a

quinpirole-induced reduction of dopamine levels is
responsible for the decreased locomotion (i.e., a

presynaptic effect), while stimulation of postsynaptic

receptors at higher doses is responsible for the increased
locomotor activity.

Furthermore, although selective D2

agonists are not capable of producing intense
stereotypies, high doses of quinpirole induce low level
stereotypies such as sniffing and rearing (Christensen,

Arnt,

& Svendsen,

1985; Meller, Bordi,

& Bohmaker,

1988.) .

Systemic administration of nonselective dopamine

agonists, which stimulate both Dl and D2 receptors,

causes

behavioral effects that are somewhat similar to the

effects of a selective D2 agonist. Specifically,
nonselective D2 agonists affect the locomotor activity of

rodents in a biphasic manner: locomotion is attenuated at

low concentrations and enhanced at higher concentrations
of the drug (Bradbury et al.,

1984; Costall et al.,

1981;

Tossman et al., 1983). At even higher doses, however,
nonselective D1/D2 agonists induce more intense behaviors
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that are not observed after treatment with a selective D2
agonist alone

(Bradbury et al.,

Vaccheri, Dall'Olio, Gandolfi,

1984; Ljungberg,

1986;

& Montanaro, 1986). For

example, high doses of apomorphine

(2-4 mg/kg)

induce a

full range of stereotyped behaviors ranging from sniffing

and rearing to intense repetitive movements such as
licking, biting,

and gnawing (Costall & Naylor,

Lepekhina & Tsitsurina,

2007; Ljungberg,

1971; Szechtman, Ornstein, Teitelbaum,

1973;

1986; Schiorring,

& Golani,

1985). A

full range of stereotyped behaviors also occur after

coadministration of selective DI and D2 agonists. Not
surprisingly, these behavioral effects can be attenuated
by systemic treatment with either a selective Dl or D2

receptor antagonist

(Arnt, 1987; Braun & Chase,

1986).

Precision Targeted Intracranial Microinjection
of Dopamine Agonists
Microinjection of Dl Agonists
Microinjection of selective Dl agonists into the

nucleus accumbens induces a variety of motor behaviors,
including locomotor activity, climbing, and contralateral

circling, among others. The behaviors induced by Dl

agonism can be antagonized by either a selective Dl

SCH23390) or D2

(e.g.,

(Dreher & Jackson,

spiperone)

1989).
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(e.g.,

receptor antagonist

In contrast, microinjection of Dl agonists into the
striatum does not produce locomotor activity, but it does

cause contralateral circling when administered
unilaterally in normosensitive rats
Naylor,

1984a; Worms, Gueudet,

(Costall, Kelly,

& Biziere,

&

1986). This

circling behavior can be attenuated by systemic

administration of either a Dl or D2 antagonist

al.,

(Worms et

1986). Importantly, microinjection of SKF38393 into

the striatum does not produce stereotyped behaviors
& Marriott,

(Gower

1982).

Microinjection of D2 Agonists
Microinjection of D2 agonists into the nucleus

accumbens results in a moderate dose-dependent increase in
locomotor activity (Breese et al.,
1991a,

1991b; Plaznik,

Stefanski,

1987; Mogenson & Wu,
& Kostowski,

1989). This

locomotor activation can be blocked by depletion of

monoamines through reserpine pretreatment or by systemic
treatment with SCH23390

(Dreher & Jackson,

1989). In

comparison, microinjecting D2 agonists into the striatum
of 6-OHDA-treated rats induces vigorous locomotion that

can be attenuated by systemic D2 antagonism and cannot be

augmented with further infusion of a Dl agonist
1990).
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(LaHoste,

.Microinjection of Nonselective or Indirect
Agonists

Anatomical and behavioral studies have shown that the
striatum is responsible for the stereotypical effects of

dopamine agonists in rodents. Specifically, early studies

showed that microinjecting dopamine into the dorsal
striatum is able to elicit stereotyped motor responses

that can be inhibited by D2 antagonism (Costall, Marsden,

Naylor,

& Pycock,

Pijnenburg,

1976; Jackson, Anden,

Honig, Van der Heyden,

& Dahlstrom,

& Van Rossum,

1975;

1976).

Furthermore, microinjecting a combination of quinpirole
and SKF38393, or the nonselective dopamine agonist

apomorphine, into the dorsal striatum also results in the

expression of stereotypy (Gower & Marriott,

1982). These

findings have been further confirmed by a number of lesion

studies showing that nigrostriatal projections are

necessary for the expression of dopamine-mediated
stereotypy (Asher & Aghajanian,

1974; Iversen & Koob,

1977; Joyce, Stinus,

1983; Kelly, Seviour,

Iversen,

& Iversen,

&

1975).

The nucleus accumbens is a critical mesolimbic

structure modulating rodent locomotor behavior through its
dopaminergic connections. For example,

coadministration of

DI and D2 receptor agonists, but not either agonist alone,
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into the nucleus accumbens results in a synergistic

increase in locomotion and, when injected unilaterally,
contralateral circling

Wise,
al.,

(Canales & Iversen,

1991; Dreher & Jackson, 1989; Fog,

1975; Mrabet, Messier,

Staton,

& Destrade,

1998; Colle &

1972; Kelly et
1989; Solomon &

1982). Although dopamine agonist studies indicate

that the striatum mediates stereotypy and the nucleus

accumbens is associated with locomotor activity, their

functions are not exclusively independent. It seems that
multiple neuronal networks,

proximal regions,

segregated in a number of

are responsible for the behavioral

response to dopamine agonism; therefore, these motor

responses are not solely mediated by one particular brain
region or circuit.

D1/D2 Synergism

The interaction between the Dl and 02 family of

receptors is an important factor affecting the expression

of dopamine-mediated behaviors. There are several studies
showing that synergistic activation of Dl and D2 receptors

is required for a variety of behaviors to be expressed.
For example, selective D2 receptor agonists

quinpirole)

(e.g.,

are capable of inducing locomotion and mild

stereotypes, although they fail to produce intense
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stereotyped behavior. However,

intense stereotypy is

apparent when selective Dl and D2 receptor agonists are
coadministered (Arnt, 1987; Braun & Chase,

1986). More

importantly, the behavioral effects of combined Dl and D2
administration can be attenuated by either a Dl or D2
receptor antagonist

(Arnt, 1987).

An interaction between the two families of dopamine

receptors is further apparent because administration of a

selective Dl antagonist

(SCH23390) not only blocks the

effects of SKF38393 but exhibits a profile similar to a

selective D2 or nonselective dopamine antagonist. More
specifically,

systemic administration of SCH23390 is

capable of attenuating locomotion and conditioned

avoidance responding, while producing catalepsy (Amalric,
Koob, Creese,

Liebman,

& Swerdlow, 1986; Gerhardt, Gerber,

1985; Gessa et al.,

&

1985). In addition, SCH23390

modulates the effects of a variety of selective and

nonselective dopamine agonists. For example,
attenuates locomotion,

stereotypy,

SCH23390

and turning induced by

selective D2 agonists such as quinpirole or pergolide
(Arnt,

Molloy,

1985; Breese & Mueller,

& Waddington,

1985; Pugh, O'Boyle,

1985). Thus, it is evident that the

Dl and D2 family of dopamine receptors interacts when

mediating a variety of behavioral responses.
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The synergistic effects of Dl and D2 receptors have

been further studied in monoamine depleted (i.e.,
reserpinized)

rats. In dopamine depleted animals,

administration of a nonselective dopamine receptor agonist
(apomorphine)

is capable of inducing locomotion and

stereotyped behavior (Arnt, 1987; Braun & Chase,

1986).

The synergistic relationship between the Dl and D2
families of receptors becomes further apparent since D2

agonists alone (quinpirole and bromocriptine) do not
elicit a comparable response even though they are capable
of augmenting locomotion in normosensitive animals

1987; Braun & Chase,

1986).

(Arnt,

Interestingly, locomotion of

reserpinized rats can be reinstated using D2 agonists but
only when it is combined with a low, and otherwise
behaviorally ineffective, dose of SKF38393

(Arnt,

1987).

Thus, it is evident that tonic activation of Dl receptors

is required for the expression of D2 mediated behaviors.

Neurochemical and Behavioral Effects of
Irreversible Dopamine Receptor
Alkylation

N-ethoxycarbonyl-2-ethoxy-l,2-dihydroquinoline

(EEDQ)

has been used extensively to study the functional

characteristics of dopamine receptors. EEDQ functions by
nondiscriminative alkylation of dopaminergic receptors
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rendering them functionless

1985; Nowak, Arnt,

(Adler, Meller,

& Goldstein,

& Hyttel, 1988). Since EEDQ

irreversibly blocks only unprotected monoamine receptors,
and does not damage neurons as a whole, it has proven to
be a useful tool for studying receptors,

and neural pathways
Giorgi & Biggio,

individual cells,

(Crawford, McDougall,

1990a; Hamblin & Creese,

& Bardo,

1994b;

1983).

Dopamine-mediated behavior have also been
successfully studied using EEDQ irreversible antagonism.

Since EEDQ is not selective to any particular dopamine
receptor subtype, dopamine receptor subtypes can be

selectively protected with exogenous antagonists
(Crawford, McDougall,

& Bardo,

1994b; McDougall, Crawford,

1994a; Crawford et al.,

& Nonneman,

1993; Nowak et

al., 1988). Sulpiride and raclopride are commonly used to
protect D2 dopamine receptors, whereas SCH23390 is used to
protect Dl dopamine receptors

Goldstein,

& Friedhoff,

Greenblatt, & Shader,

(Meller, Bohmaker,

1985; Miller, Lumpkin, Galpern,

1991). Systemic administration of

EEDQ induces severe catalepsy and attenuates
amphetamine-induced stereotypy of adult rats

al.,

1968; Hamblin & Creese,

& Roth,

1983; Henry,

(Belleau et

Joseph, Kochman,

1987). Rats treated systemically with EEDQ also

exhibit attenuated levels of NPA-induced sniffing and oral
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activities for 4-8 days, after which responsiveness
returns to normal

addition,

(Bordi, Carr,

& Meller,

systemic EEDQ treatment

1989).

In

(25 mg/kg) has been

shown to reliably and substantially reduce the percentage
(down to 7% of controls) and D2

of Dl

(down to 8% of

controls) dopamine receptors in striatal samples
et al.,

1994b; Crawford, McDougall,

Rowlett,

(Crawford

& Bardo,

1992).
Functional properties of dopamine receptors have also

been studied after unilateral administration of EEDQ into
various motor related brain regions.

In this model,

nonselective unilateral inactivation of dopamine receptors

is responsible for a marked dose-dependent increase in
ipsilateral movement following quinpirole treatment
(Giorgi & Biggio,

1990a). Interestingly, systemic SKF38393

treatment did not cause ipsilateral rotation but did
potentiate quinpirole-induced locomotion (Giorgi & Biggio,

1990a). This effect may be due to a more extensive Dl
receptor reserve or deactivation of a larger percentage of

Dl receptors may be required for ipsilateral movement. In
summary, irreversible inactivation of dopamine receptors

via EEDQ alkylation is a useful technique to study the

functional properties of Dl and D2 dopamine receptors.
allows one to examine the role of Dl and D2 receptors
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It

without relying on the acute presence of a reversible

dopamine receptor antagonist.

Ontogeny of Dopamine-Mediated Behavior
Dopamine-mediated behavior varies across ontogeny due
to maturational changes in dopamine system functioning
(Broaddus & Bennett,

Walters,

1990; Hedner & Lundborg,

1985; Lin &

1994). Like adults, young animals are capable of

responding to Dl and D2 agonists and the synergism between

receptors is apparent at birth. Some quantitative
behavioral differences are apparent, however, because the

Dl agonist SKF38393 elicits more pronounced locomotor

activity in preweanling animals than adults
Setler,

1981; Moody & Spear,

(McDevitt &

1992). Furthermore,

greater

doses of SKF38393 are needed to evoke grooming responses

in young rats, thus suggesting quantitative changes in
either Dl receptors or the pharmacokinetics of SKF38393

(McDougall, Arnold,

& Nonneman,

1990; Moody & Spear,

1992).

Systemically administered quinpirole is capable of

producing forward locomotion and stereotyped behavior
(intermittent licking, sniffing, and reversed locomotion),
which is comparable to adult rats
Moody & Spear,

(Lal & Sourkes,

1973;

1992). Moreover, like adults, preweanling
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rats display a biphasic behavioral reaction to quinpirole,

with lower doses augmenting and higher doses attenuating
locomotion (Moody & Spear, 1992; Van Hartesveldt et al.,

1994). This biphasic effect is also apparent when
R(-)-propylnorapomorphine

(NPA)

is infused into the

striatum of young rats. Specifically,

(0.1 mg/kg)

low doses of NPA

increase forward locomotion, while higher

doses of NPA (1.0 mg/kg) do not

(Charntikov et al., 2008).

Adult-like stereotyped behavior has also been reported
following apomorphine administration in neonatal,
and preweanling rats

(Lal & Sourkes,

infant,

1973). Therefore,

it

seems that young rats behave in a qualitatively similar
manner to adults when treated systemically with Dl, D2, or
nonselective dopamine agonists, or when intracerebrally

injected with the D2 agonist NPA.
Age-dependent differences in dopamine receptor
functioning and turnover have also been studied using

EEDQ. In young animals systemic EEDQ

(25 mg/kg)

treatment

is capable of significantly reducing the number of

available Dl

(down to 21% of controls)

and D2

(down to 35%

of controls) dopamine receptors in striatal tissue samples

(Crawford et al.,

1992,

1994b). Furthermore, EEDQ has been

used successfully to study a variety of agonist-induced
behaviors in animals

(Cameron & Crocker,
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1989; Double &

Crocker, 1990). Like adults, preweanling rats pretreated

with SCH23390 and sulpiride, in order to preserve DI and
D2 dopamine receptors, do not exhibit typical

amphetamine-induced behaviors (Crawford et al., 1994b).
Unfortunately,

EEDQ has only been administered

systemically to preweanling rats, thus the advantages

inherent to site-specific microinjections of EEDQ have not

been utilized in young animals.
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CHAPTER SIX
KAPPA OPIOID-MEDIATED BEHAVIOR

Introduction

Kappa opioid receptors are capable of modulating a

variety of physiological and behavioral responses in adult

rats and mice,

including analgesia,

motoric behaviors

reward, and unlearned

(e.g., locomotion, grooming,

and sniffing). In terms of analgesia,

administration of exogenous

endogenous

(dynorphin)

systemic

(e.g. U50488 and U69593) or

kappa opioid agonists is capable of

inducing antinociception
Herman & Goldstein,

rearing,

(Gogas, Levine,

1985; Millan et al.,

& Basbaum,

1996;

1989). In

addition, systemic administration of U50488 or dynorphin
attenuates morphine- and p-endorphin-induced analgesia in
a dose-dependent manner when tested on the hot plate or

tail flick task (Friedman,

Ramarao, Jablonski, Rehder,
& Chen,

1994; Tulunay,

terms of reward,

Jen, Chang, Lee,
& Bhargava,

Jen, Chang, Loh,

& Loh,

1981;

1988; Tao, Hwang,

& Lee,

1981). In

kappa opioid agonists lack reinforcing

properties and are neither self administered or induce a

conditioned place preference (Dykstra, Preston,

& Bigelow,

1997). However, systemic administration of U50488 is able
to attenuate the rewarding effects of morphine
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(a kappa

and cocaine (an indirect dopamine agonist)

opioid agonist)

on self administration and conditioned place preference

tasks

(Crawford, McDougall, Bolanos, Hall,

Funada et al.,

Van Ree,

1993; Kuzmin,

& Berger,

Semenova, Gerrits,

1995;

Zvartau,

&

1997). Importantly, these U50488-induced

behavioral effects are sensitive to kappa opioid
antagonists

(e.g., nor-binaltorphimine),

thus confirming

that U50488's actions are mediated by the kappa opioid

receptor (Funada et al.,
& Archer,

1993; Glick, Maisonneuve, Raucci,

1995) .

Adult Rats and Mice: Unlearned Motor Movement

Systemic Kappa Opioid Administration: Striatal
Actions
Stimulation of kappa opioid receptors in adult

rodents produces a marked reduction in motoric activity
(Crawford et al.,
Stewart,

1995; Jackson & Cooper,

1992; Ukai & Kameyama,

1988; Leyton &

1985). Specifically,

systemic administration of U50588 results in decreased

levels of forward movement, rearing, and grooming (Jackson
& Cooper,

1988; Leyton & Stewart,

1.992; Ukai & Kameyama,

1985). In addition to its ability to reduce basal
locomotor activity,

U50488 attenuates cocaine-induced

locomotion (Crawford et al.,

1995). The locomotor

inhibiting properties of kappa opioid receptor agonism can

54

be reversed by nor-binaltorphimine, thus indicating that

kappa opioid receptors are responsible for modulating

these unlearned behaviors

(Kuzmin, Sandin, Terenius,

&

Ogren, 2000).
The ability of kappa opioid agonists to attenuate the
locomotion of adult animals appears to result from the

modulation of the mesolimbic and nigrostriatal dopamine

pathways. These dopaminergic pathways project to the
striatum and nucleus accumbens and are known to mediate

locomotor activity as well as other unlearned motoric

behaviors

(Costall et al., 1976; Pijnenburg et al.,

Solomon & Staton,

1976;

1982). Interestingly, perfusion of kappa

opioid agonists into the striatum and nucleus accumbens of
adult rats attenuates dopamine release and, most

importantly, decreases locomotion (Di Chiara & Imperato,
1988; Donzanti, Althaus, Payson,
Maisonneuve, Archer,

& Glick,

& Von Voigtlander,

1994; Spanagel, Herz,

1992;
&

Shippenberg, 1990) . The locomotor-inhibiting effects of
kappa opioid agonists are observed in both normosensitive

and psychostimulant-treated adult rats
1995; Di Chiara & Imperato,
Leyton & Stewart,

(Crawford et al.,

1988; Jackson & Cooper,

1992; Waddell & Holtzman,

198 8;

1998). The

neural mechanisms responsible for these behavioral effects

appear to involve presynaptic kappa opioid receptors.
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Stimulation of presynaptic kappa opioid receptors,

located

on the terminals of mesolimbic and nigrostriatal dopamine

neurons, results in decreased dopamine release from the

(Di Chiara & Imperato,

host terminal fibers

Maisonneuve et al., 1994; Spanagel et al.,
Herz,

& Shippenberg,

1988;
1990; Spanagel,

1992). Thus, decreased dopaminergic

transmission seems to be responsible for the reduction of
locomotion following kappa opioid agonist administration.
Central Kappa Opioid Administration: Nigral
Actions

Surprisingly, microinjecting kappa opioid agonists

into the substantia nigra pars reticulata,

the basal ganglia,

a nucleus in

cause a dramatic increase in the

locomotor activity of adult rats. Specifically, unilateral

administration of U50488 or dynorphin produces a marked
increase in the contralateral circling of adult rats

(Friederich,

et al.,

Friederich,

1987; Herrera-Marschitz

1986; Herrera-Marschitz, Hokfelt,

Terenius,

Ungerstedt,

&

1983; Herrera-Marschitz, Hokfelt, Ungerstedt,

Terenius, •& Goldstein,
Patrick,

& Walker,

& Walker,

1984; Matsumoto, Brinsfield,

1988; Morelli & Di Chiara,

1985). This

effect seems unrelated to dopaminergic activity,

since

lesioning the nigrostriatal pathway does not disrupt the
contralateral circling induced by unilateral
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administration of a kappa opioid agonist into the
substantia nigra pars reticulata
Morelli & Di Chiara,

(Matsumoto et al.,

1985; Walker, Thompson,

1988;

Frascella,

&

Friederich, 1987). Kappa opioid receptors within the
substantia nigra pars reticulata are predominantly located
on GABAergic output neurons that project to the superior

colliculus and ventromedial thalamus
Imperato,

& Porceddu,

(Di Chiara, Morelli,

1982; Morelli & Di Chiara,

1985).

Summary
Kappa opioid receptor systems seem to be indirectly

involved in modulating locomotion of rodents. Adult

animals treated systemically with a kappa opioid agonist
exhibit reduced levels of locomotion, which seems to be

the result of decreased striatal and accumbal dopamine

release. Animals given a unilateral microinjection of a
kappa opioid agonist into the substantia nigra pars

reticulata exhibit an augmented locomotor response.

Specifically,

stimulating kappa opioid receptors in the

substantia nigra pars reticulata inhibits GABAergic output

neurons which, in turn, causes the disinhibition of the

tectal and thalamic premotor systems. Depressed GABAergic
output to the premotor areas, such as the superior

colliculus and thalamus, results in disinhibition of these
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systems and, as a consequence, elevated locomotor

activity.

Preweanling Rats and Mice: Overview
In young animals the central nervous system undergoes

maturational changes that result in different behavioral
patterns, which can vary depending on the stage of

development

(Broaddus & Bennett,

1990; Clark, Garret,

&

Platt, 2001; Leslie & Loughlin, 1993). The maturation of

neuronal circuits produces both quantitative and
qualitative behavioral changes which can be revealed

through .various pharmacological interventions (Myslivecek
& Hassmannova,

1979; Spear,

1979; Zhang & Pasternak,

1981). One of the clearest examples of an ontogenetic
pharmacological effect involves activation of the kappa
opioid system. Specifically,

stimulation of kappa opioid

receptors produces dramatically different effects in young
and adult rats. Systemic administration of selective kappa
opioid agonists

(e.g., U50488)

attenuates locomotor

activity of adult rats, while paradoxically causing a

dramatic increase in the locomotion of preweanling rats
(Carden, Barr,

& Hofer,

Di Chiara & Imperato,

1991; Collins et al.,

1988; Duke et al.,
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1998, 2000;

1997; Jackson &

Cooper,

1988; Kehoe & Boylan,

1992; McDougall et al.,

1994; Leyton & Stewart,

1997; Ukai & Kameyama,

1985).

Kappa opioid-mediated locomotion in preweanling

animals is not mediated by the dopaminergic system, but
rather seems to be dependent on GABAergic outputs from the

substantia nigra pars reticulata to premotor systems,

such

as the superior colliculus and ventromedial thalamus
(Collins et al., 2000; Zavala, Yoshida, Osburn,

&

McDougall, 2002). The substantia nigra pars reticulata has

been established as an activation site for U50488-induced
behavior in 18-day-old rats

(Collins et al., 2000).

Specifically, bilateral microinjections of

nor-binaltorphimine, a kappa opioid antagonist, into the

substantia nigra pars reticulata attenuates the locomotor
activating effects of systemically administered U50488

(Collins et al., 2000). The elevated motor response to
kappa opioid receptor agonism is due to GABAergic
disinhibition of motor pathways projecting from substantia
nigra pars reticulata to the ventromedial thalamus and

superior colliculus

(Zavala et al., 2002). Thus, the kappa

opioid-induced locomotor activity of preweanling rats is

mediated by nigrotectal and nigrothalamic GABAergic
projections originating in the substantia nigra pars

reticulata and is not due to kappa opioid receptor
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stimulation within accumbal and striatal areas

al., 2000; Morelli & Di Chiara,
1992).
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(Collins et

1985; Thompson & Walker,

CHAPTER SEVEN
CONCLUSION

Although much is known about the early ontogeny of

the dopamine and kappa opioid systems, how these systems

interact is not fully understood.

Interestingly,

it

appears that the dopamine system is capable of modulating

the U50488-induced locomotor activity of preweanling rats.
For example,

stimulation of D2 receptors, but not Dl

receptors, fully attenuates the locomotion induced by
kappa opioid receptor agonists

McDougall et al.,

1997,

(Collins et al.,

1998;

1999). Specifically, systemic

administration of the D2/D3 agonist quinpirole blocks
U50488~induced locomotor activity,

suggesting that these

receptor subtypes are important for the dopamine/kappa
opioid interaction.

Furthermore,

systemic or intracranial administration

of NPA into the dorsal striatum is able to attenuate the
kappa opioid-induced locomotor activity of young rats

(Charntikov et al., 2008; Duke et al.,
al.,

1997,

1999; Nazarian et al.,

1997; McDougall et

1999). This effect

cannot be attributed to NPA's ability to induce

stereotypy, since coadministration of NPA and U50488 has
been shown to reduce stereotypy relative to when NPA is
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administered alone

(Duke et al.,

1997; McDougall et al.,

1999). Since NPA is somewhat selective for D2 dopamine
receptors,

it appeared likely that this kappa

opioid-induced locomotion is mediated, at least partially,
by dorsal striatal neuronal populations expressing D2

receptors. Paradoxically, however, the indirect pathway,
which has mainly D2 receptor input, does not seem to

mediate kappa opioid-induced locomotion.

For example,

lesions to critical regions of the indirect pathway (i.e.,
the globus pallidus and subthalamic nucleus)

were unable

to disrupt NPA's ability to attenuate the kappa
opioid-induced locomotor activity of young rats

(Charntikov et al., 2008).
There are three possible explanations for why

bilateral lesions of the indirect pathway were unable to
disrupt NPA's locomotor modulating effect.

First,

it is

feasible that electrolytic lesions of the indirect pathway
were not complete,

leaving small populations of neurons

within that pathway intact and operational. This
possibility seems unlikely, however, because additional

behavioral data from that study suggest that lesions to
the globus pallidus and subthalamic nucleus were

sufficient to disrupt the indirect pathway
Dewar, Jenner,
i

& Marsden,

(see also

1983; Joel et al., 1998).
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Second,

it is possible that D2 receptors located on

the striatonigral neurons of the direct pathway are
responsible for NPA's ability to attenuate U50488-induced

locomotor activity in preweanling rats. Although DI
receptors predominate on striatonigral neurons, previous

studies have shown that both striatonigral and
striatopallidal pathways exhibit some level of

colocalization (Aizman et al., 2000; Deng et al., 2006;
Hersch et al.,

1995a; Lester,

1993; Meador-Woodruff et al.,

Fink, Aronin,

& DiFiglia,

1991; Surmeier -et al.,

1992,

1993). Even though it has been established that D2

receptors are located on striatonigral neurons, the
functional properties of these receptors are not known.
Lastly,

it is possible that NPA's .ability to

stimulate DI receptors in the dorsal striatum may be
responsible for modulating kappa opioid-mediated

locomotion. Although NPA is more selective for the D2

receptor subtype, it also has affinity for the Dl dopamine
receptor. The ability of NPA to induce intense stereotypy,
relative to quinpirole for example,

is evidence of NPA's

ability to stimulate both Dl and D2 receptors
al.,

(Bordi et

1989; Meller et al., 1988). Since the direct

(striatonigral) pathway is mainly composed of neurons
expressing Dl receptors and projects from the dorsal
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striatum to the substantia nigra pars compacta

brain area mediating U50488-induced locomotion)

(i.e., the

it is

possible that Dl receptors of the direct pathway are

responsible for modulating kappa opioid-mediated locomotor

activity.

The purpose of this thesis was to further investigate
the relationship between dopamine and kappa opioid

networks in the preweanling rat. Specifically,

I attempted

to answer whether Dl. or D2 receptors

are

(or both)

responsible for modulating the kappa opioid-mediated
locomotor activity of preweanling rats. To test this
experimental idea I employed EEDQ, which irreversibly

inactivates dopamine receptors. I wanted to use this

pharmacological agent because it can later be adapted for

studying the underlying pathways mediating dopamine/kappa
opioid interactions.

I also employed the straight forward

procedure of administering selective Dl and D2 agonists in
order to determine what receptor type modulates kappa

opioid-mediated locomotor activity.

In Experiment 1,

I tested whether intrastriatal

administration of EEDQ (an irreversible monoamine receptor
antagonist)

blocked NPA's ability to attenuate

U50488-induced locomotion.

It was hypothesized that

microinjecting EEDQ into the dorsal striatum would block
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NPA's actions. In Experiment 2,

I originally planned to

test whether Dl or D2 receptor stimulation,

or concomitant

stimulation of Dl and D2 receptors, by NPA is responsible

for attenuating the U50488-induced locomotor activity of
preweanling rats. However, because EEDQ did not block
NPA's actions in Experiment 1, an alternate follow-up

experiment was done. Specifically,

in Experiment 2A,

I

microinjected distilled water, quinpirole (a selective

D2/D3 agonist), or SKF38393

(a selective Dl agonist)

into

the dorsal striatum following systemic saline or U50488

administration. It was hypothesized that microinjecting

SKF38393, but not quinpirole, would attenuate the kappa
opioid-mediated locomotor activity of preweanling rats.
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CHAPTER EIGHT

METHODS

Experimental Procedures
Subjects

Subjects were 240

(n = 8 per group) male and female

rats of Sprague-Dawley descent (Charles River), born and
raised at California State, San Bernardino

(CSUSB).

Litters were culled to 10 at PD 3 and were kept with dam

until the end of experiment

(PD 18). Rats were kept in the

colony room under a 12 hour light/dark schedule and were
maintained at 21-23 °C. All rats were treated according to

the "Guide for the Care and Use of Mammals in Neuroscience
and Behavioral Research"

(National Research Council,

2003)

under a research protocol approved by the Institutional

Animal Care and Use Committee of CSUSB.
Apparatus
Behavioral assessment was performed in commercially

available automated locomotor activity chambers

(25 x 25 x 41 cm; Coulbourn Instruments)
four transparent Plexiglas walls,

consisting of

a gray plastic composite

floor, and an open top. Locomotion was measured by
interruption of two sets of photobeam arrays horizontally

positioned to measure rodent locomotor activity.
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Drugs

U50488 methanesulfonate was dissolved in saline and

administered intraperitonealy (i.p.) at a volume of
5 ml/kg. R(-)-propylnorapomorphine hydrochloride

(NPA),

quinpirole, and SKF38393 were dissolved in distilled water
and administered intracranially (i.c.) at a volume of
0.5 pl per side. EEDQ was dissolved in DMSO and injected

intracranially (i.c.) at a volume of 0.5 pl per side
(Giorgi & Biggio,

1990b). All drugs were purchased from

Sigma-Aldrich (St. Louis, MO).
Surgery
All animals underwent cannulae implantation surgery
on PD 16. Anesthesia was induced by administering

isoflurane

(5%/5 min in 100% oxygen during the induction

phase and 2-3% in 100% oxygen during the maintenance
phase) via a nose mask. Prior to surgeries, all rats were

administered ketoprofen 2 mg/kg (i.p.)

lidocaine solution (1%)

and a topical

for pain management. A Cunningham

Neonatal Rat Adapter attached to a standard Kopf
stereotaxic apparatus was used to immobilize subjects

during all surgical procedures. Microinjection guide
cannulae (C232G; 22-gauge,

5 mm length; Plastics One;

Roanoke, VA) were implanted 1 mm above the dorsal striatum
(A +6.5, L 2.4, V 5.6). Coordinates for the dorsal
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striatum were obtained from the developing rat brain atlas
of Sherwood and Timiras

(1970). Guide cannulae were

anchored to the scull using cyanoacrylate gel followed by

dental cement

(Lang Dental; Wheeling,

IL). Following

cranioplasty, all animals were sutured and placed in a

heated incubation chamber until fully recovered; subjects

were then returned to dam. Post-operative monitoring was
performed in order to assess subject responsiveness and
dam acceptance. All rats underwent behavioral assessment
48 hr later.
Microinj ection Procedure
Stainless steel stylets were replaced by an internal
injection cannulae

(C2321-5-SPC; 28-gauge, 1 mm projection

length; Plastics One; Roanoke, VA), which protruded 1 mm

below the tip of the guide cannula.

Injection cannulae

were attached via polyethylene tubing (i.d.: 28 mm; Becton

Dickinson; Sparks, MD) to a 10 pl syringe

(1.801N,

Hamilton; Reno, NV), which was mounted onto the
microinjection pump (SP210IW; World Precision Instruments;

Sarasota, FL). Cannulae were left in place for 1 min and
the compound was then delivered at a constant rate over a
60 s period.

Following microinjection,

cannulae were left

in place for an additional 1 min after which rats were
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returned to the activity chambers.

During the inj ection

procedure all animals were gently hand-held.

Behavioral Procedures
Experiment 1

The first experiment tested the ability of

intrastriatal EEDQ to block the NPA-induced reduction of
kappa opioid-mediated locomotor activity. In addition,
this experiment was designed to determine whether dopamine

receptor inactivation alters U50488-induced locomotion.

This was a mixed between/within factorial design with four
independent variables: condition
pre-drug

(EEDQ or saline),

(U50488 or saline), post-drug

(0,

5,

10,

or 20 pg

NPA), and time block (see Figure 2). The dependent

variable was distance traveled scores. A total of 128 rats

(n = 8 per group) were used in Experiment 1.

On PD 17

(24 hr after surgery), rats received

bilateral infusions of vehicle or EEDQ (200 pg;

0.5 pl per

side). After an additional 24 hr (i.e., on PD 18),

EEDQ-

and vehicle-treated rats were placed for 20 min in the

automated locomotor activity chambers

(see Figure 3).

Immediately following this 20 min baseline period,

subjects were injected (i.p.) with U50488

(5 mg/kg)

saline and returned to the activity chambers for
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or

additional behavioral assessment. After 20 min,

rats were

microinjected with either distilled water or NPA (5,
or 20 pg)

10,

into the dorsal striatum and returned to the

activity chambers for another 40 min.

Immediately

following behavioral testing all subjects underwent
histological examination to determine the accuracy of

cannulae placement.
Experiment 2

The second experiment was designed to test whether

Dl, D2, or D1+D2 receptors located in the dorsal striatum
mediated the U50488-induced locomotor activity of

preweanling rats. All animals in Experiment 2 would have
received one of four receptor protection treatments on PD
17

(24 hr after cannulae implantation). Specifically,

different groups of rats would have been systemically
treated (i.p.) with either SCH23390

(1 mg/kg),

(100 mg/kg), SCH23390 + sulpiride, or saline

Crocker, 1989; Crawford et al.,

sulpiride

(Cameron &

1992; Giorgi et al.,

1990). These drug combinations would have been used to
protect Dl receptors, D2 receptors, or both Dl and D2

receptors.
Experiment 2A

As mentioned in the introduction, because Experiment
1 failed (i.e., EEDQ did not block NPA-induced behaviors)
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Experiment 2 was not conducted. Instead, Experiment 2A was
designed to assess whether stimulation of Dl or D2

receptors, via intracranial administration of highly

selective dopamine agonists, modulates the U50488-induced
locomotor activity of preweanling rats. This was a mixed
between/within factorial subject design with three

independent variables: pre-drug (saline or U50488),

post-drug (distilled water, quinpirole,

or SKF38393), and

time block (see Figure 4). The dependent variable was

distance traveled scores. A total of 112 rats

(n = 8 per

group) were used in Experiment 2A.
On PD 16 preweanling rats received intracranial

cannulations. On PD 18, these rats were placed for 20 min

in the testing chambers for assessment of locomotor

activity (see Figure 5). Immediately afterwards, rats were

injected (i.p.) with either saline or U50488 and placed

back in the testing chambers for an additional 20 min.
Rats then received dorsal striatal infusions of distilled

water, quinpirole
SKF38393

(10, 20, or 30 pg; 0.5 pl per side), or

(10, 20, or 30 pg; 0.5 pl per side) and were

returned to the chambers for an additional 40 min of

testing. Histological assessment of cannulae placement
immediately followed completion of behavioral testing.
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Histology

All rats received an overdose of pentobarbital after
which brains were removed and perfused with 4%
paraformaldehyde solution.

Following a fixation period

(48-72 hr), tissue was cryoprotected in a 20% sucrose
solution for an additional 24-48 hr. Coronal brain
sections

(70 pm) were taken using a cryostat. All tissue

samples were stained with thionin for cannulae placement
verification.

Statistical Analysis
Analysis of variance (ANOVA)

for repeated measures

(using SPSS general linear model) was used for the

statistical analysis of locomotor activity.

Data were

analyzed in 5-min time blocks. Statistically significant

higher order interactions were further analyzed by one- or
two-way ANOVAs and followed, if necessary, by Tukey's HSD

(for between group comparisons) or Dunnett's
comparison to a control group) post hoc tests

(for

(p < 0.05).

Violations of sphericity (as determined by Mauchly's
sphericity test) were further corrected using Huynh-Feldt

degrees of freedom adjustments and are indicated in the
Results section using a superscripted "a". In order to
control for litter effects, no more than one subject from
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a litter was assigned to a particular group. An equal

number of male and female rats were assigned to each

group.
For Experiment 1, there was four independent

variables: a) condition (EEDQ or vehicle), b) pre-drug

(U50488 or saline), c) post-drug (0,

NPA) , and d) time blocks

5,

10,

or 20 pig of

(see Figure 2) . Because of

ongoing experimental manipulations, separate ANOVAs were

used to analyze time blocks 1-4
5-8

(habituation), time blocks

(U50488 vs saline), and time blocks 9-16

vehicle). The first four time blocks
analyzed using a 2 * 4

Time blocks 5-8

(NPA vs

(0-20 min) were

(condition x time block) ANOVA.

(20-40 min) were analyzed by a 2 x 2 * 4

(condition x pre-drug x time block) ANOVA. Time blocks
9-16

(40-80 min) were analyzed using a2x2
4x8
*

(condition x pre-drug x post-drug x time block) ANOVA.

Significant higher order interactions were further
assessed using one- or two-way ANOVAs.

For Experiment 2A, there were three independent

variables: a) pre-drug (saline or U50488), b) post-drug

(distilled water, quinpirole, or SKF38393) , and c) time
blocks

(see Figure 4). Separate ANOVAs were used to

analyze time blocks 1-4

(habituation), time blocks 5-8

(U50488 vs saline), and time blocks 9-16 (quinpirole vs
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SKF38393 vs distilled water). The first four time blocks

(0-20 min) were analyzed using a one-way (time block)

ANOVA. Time blocks 5-8
2x4

(20—40 min) were analyzed using a

(pre-drug * time block) ANOVA. Time blocks 9-16

(40-80 min) were analyzed using a 2 * 7 * 8

(pre-drug x post-drug x time block) ANOVA.

Histological assessment of cannulae placement was
performed by two observers blind to experimental

conditions. Cannulae placements were graphically mapped on
coronal sections taken from Paxinos and Watson's The rat

brain: in stereotaxic coordinates (1998) . Only subjects

with accurate cannulae placements were included in the
statistical analysis.
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EEDQ, irreversible monoamine receptor alkalizing agent; U50488, selective kappa opioid
agonist; NPA, nonselective dopamine agonist._________________________________________

Figure 2. Proposed Independent Variables for Experiment 1
(2 x 2 x 4 Design)
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Habituation occurred during the first 20 min (time blocks 1-4) after which rats were injected
(i.p.) with either U50488 or saline. Rats were then immediately returned to the testing chamber
for an additional 40 min of locomotor testing. At the end of time block 8 all rats were given
striatal infusions (i.c.) of NPA (0, 5, 10, or 20 pg) and returned to the chamber for 40 min of
additional behavioral testing.

Figure 3. Representation of the Timeline for Experiment 1

Experiment 2A

I

Systemic
Activation of
kappa-opioid
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(PD
18)
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|
Administration of
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•US0488

• Quinpirole 10 pg

•Saline

•Quinpirole 20 pg

• Distilled Water

•Quinpirole 30 pg

•SKF38393 10 pg
•SKF38393 20 pg
•SKF38393 30 pg

Quinpirole, selective D2 agonist; SKF38393, selective D1 agonist; U50488, selective kappa
opioid agonist.

Diagram of Independent Variables for Experiment

Figure 4.

2A (2 x 7 Design)
f

75

1Q-20 mln

I Time Blocks 1-4

II

rr:——
- * locoMotion-:

i Chamber
JHabitusSianr

i

-4

Rats were habituated to the apparatus during the first 20 min (time blocks 1-4). At the end of
the time block 4 all rats were injected (i.p.) with either U50488 or saline. Rats were then
immediately returned to the locomotor chambers for an additional 20 min of behavioral testing.
At the end of time block 8 all rats were infused (i.c.) with either quinpirole (10, 20, or 30 pg),
SKF38393 (10, 20, or 30 pg), or distilled water and returned to the chambers for 40 min of
additional behavioral testing.

Figure 5. Representation of the Timeline for Experiment 2A

CHAPTER NINE
RESULTS

Experiment 1

Habituation (Time Blocks 1-4)
Overall,

rats treated with EEDQ had greater distance

traveled scores (i.e., locomotor activity) than rats
treated with DMSO (see Figures 6 and 7, compare left

panels)

[condition main effect,

p < 0.05], Specifically,

F(l,

126) = 4.85,

the locomotor activity of

DMSO-treated rats declined progressively across time
blocks 1-4, while the locomotor activity of EEDQ-treated
rats was significantly lower than controls on time block 1

and higher than controls on time blocks 3 and 4
[acondition x time interaction,

F(2, 233) = 31.48,

p < 0.001; Tukey HSD tests].

U50488 Systemic Treatment

(Time Blocks 5-8)

DMSO Condition. Among the DMSO-pretreated rats,
U50488 significantly enhanced locomotor activity when
compared to saline-treated controls

top and bottom middle panels)

F(l,

(see Figure 6,

compare

[pre-drug main effect,

62) = 102.35, p < 0.001]. Specifically,

U50488-treated rats showed significantly greater locomotor
activity on time blocks 5-8 in comparison to
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saline-treated rats

[apre-drug x time interaction,

F(2, 107) = 35.80, p < 0.001; Tukey HSD tests].

EEDQ Condition. Among the EEDQ-pretreated rats,
U50488 significantly enhanced locomotor activity when
compared to saline controls, with differences between the
U50488- and saline-treated rats being apparent on time

blocks 6-8

panels)

(see Figure 7, compare upper and lower middle

[pre-drug main effect,

F(l,

62)

= 59.11,

p < 0.001; apre-drug x time interaction,
F(2, 112) = 36.86, p < 0.001; Tukey HSD tests].

In

addition, rats receiving U50488 showed a progressive

increase in locomotor activity across time blocks 5-8

[Tukey HSD tests].
DMSO vs. EEDQ. On time blocks 5-7, rats pretreated

with EEDQ and saline showed significantly greater
locomotor activity than rats treated with DMSO and saline

(see Figures 6 and 7, compare upper middle panels)
[condition main effect, F(l, 62) = 20.05, p < 0.001;
Condition x time interaction,

F(2, 111.)

= 7.26,

p < 0.001; Tukey HSD tests].
EEDQ-pretreated rats given U50488 showed

significantly greater locomotor activity than rats given
DMSO and U50488
*

panels)

(see Figures 6 and 7, compare lower middle

[condition main effect,
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F(l,

62)

= 12.57,

p < 0.001]. Differences between the EEDQ-U50488 and

DMSO-U50488 groups were apparent on time blocks 6-8
Figures 6 and 7, compare lower middle panels)
x time interaction,

F(2,

(see

[acondition

109) = 11.56, p < 0.001; Tukey

HSD tests].
Dorsostriatal NPA Infusions (Time Blocks 9-16)
An omnibus ANOVA assessing time blocks 9-16 resulted

in a significant four-way interaction

[acondition x pre-drug x post-drug x time block

interaction, F(10, 392) = 3.43, p < 0.05). Because of the
significant interaction separate ANOVA's were conducted.

DMSO Condition: Saline Pretreatment. Among the DMSO
rats pretreated with saline, NPA (5,

10 or 20 pg)

infusions resulted in greater locomotor activity when
compared to controls

(see Figure 6, right upper panel)

[post-drug main effect,

F(3, 28) = 22.48, p < 0.001;

Dunnett tests]. This effect did not differ according to

dose or time block.
DMSO Condition: U50488 Pretreatment. On time block 9,
U50488-pretreated rats infused with NPA (5,

10, and 2.0 pg)

had significantly greater locomotor activity than controls
(0 pg NPA)

(see Figure 6, lower right panel)

[apost-drug x time block interaction,

F(16,

150) = 8.32,

p < 0.001; Dunnett tests]. Rats infused with 20 pg NPA
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showed significantly less locomotor activity than controls
on time blocks 11-16

(see Figure 6, lower right panel).

Rats infused with the lower doses of NPA (5 or 10 pg)

did

not differ from controls on time blocks 10-16.

EEDQ Condition: Saline Pretreatment. Among the EEDQ
rats pretreated with saline, NPA (5, 10 or 20 pg)
infusions resulted in significantly greater locomotor

activity than control rats

(0 pg NPA) when collapsed

across time blocks 9-16 (see Figure 7, upper right panel)
[post-drug main effect,

F(3, 28)

= 11.00, p < 0.001;

Dunnett tests]. This effect did not differ according to

time block.

EEDQ Condition: U50488 Pretreatment. Among the EEDQ
rats pretreated with U50488,

20 pg)

infusions of NPA (5,

10 or

significantly increased locomotor activity when

collapsed across time blocks 9-16 (see Figure 7,

right panel)

[post-drug main effect,

F(3, 28)

lower

= 8.11,

p < 0.001; Dunnett tests]. This effect did not vary
according to time block.

EEDQ versus DMSO Condition: Saline Pretreatment.
Among the saline groups, EEDQ-pretreated rats showed

significantly greater locomotor activity than
DMSO-pretreated rats
right panels)

(see Figures 6 and 7, compare upper

[condition main effect, F(l,
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56)

= 47.43,

p < 0.001]. When collapsed across time blocks 9-16,
EEDQ-pretreated rats infused with NPA (5,

10,

or 20 pg)

were significantly more active than DMSO-pretreated rats
in the same treatment groups
upper right panels)

(see Figures 6 and 7, compare

[condition * post-drug interaction,

F(3, 56) = 3.88, p < 0.05; Tukey HSD tests].

EEDQ versus DMSO Condition: (J50488 Pretreatment.
Among the U50488 groups, EEDQ-pretreated rats showed

greater locomotor activity than DMSO-pretreated rats

(see

Figures 6 and 7, compare lower right panels)

[condition x post-drug interaction, F(l, 56) = 57.59,
p < 0.001]. On time blocks 10-16, EEDQ-pretreated rats
infused with NPA (5,

10 or 20 pg)

exhibited significantly

greater locomotor activity than DMSO-pretreated rats

infused with the same doses of NPA (see Figures 6 and 7,
compare right lower panels)

block interaction, F(10,

^condition x post-drug x time

195) = 6.15, p < 0.001; Tukey HSD

tests). Among the control groups

(i.e., rats given 0 pg

NPA), distance traveled scores did not vary after EEDQ

pretreatment.
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DMSO-Condition

5-Min Time Blocks

All rats were habituated to the testing chambers for 20 min (time blocks 1-4) and received
systemic injections of either saline or U50488 at the end of time block 4. All rats were infused
with NPA (0, 5, 10, or 20 pg) at the end of time block 8 and immediately returned to the testing
chamber for an additional 40 min. ^Significantly different from rats in saline pre-drug condition
at the same time block (pre-drug x time interaction). bSignificantly different from rats given
U50488 and 0 pg NPA (post-drug x time block interaction). Significantly different from rats
given saline and 0 pg NPA (post-drug main effect)._______________________________________

Figure 6. Mean Distance Traveled Scores of DMSO-Pretreated
Rats during the Testing Session
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5-Min Time Blocks

All rats were habituated to the testing chambers for 20 min (time blocks 1 -4) and received
systemic injections of either saline or U50488 at the end of time block 4. All rats were injected
with NPA (0, 5, 10, or 20 pg) at the end of time block 8 and immediately returned to the testing
chamber for an additional 40 min. Significantly different than rats in the saline pre-drug
condition at the same time block (pre-drug x time interaction). Significantly different from rats
given U50488 and 0 pg NPA (post-drug main effect). Significantly different from rats given
saline and 0 pg NPA (post-drug main effect).____________________________________________

Figure 7. Mean Distance Traveled Scores of EEDQ-Pretreated

Rats during the Testing Session
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Experiment 2A

Habituation (Time Blocks 1-4)
During habituation, rats showed a decline in

locomotor activity that was evident across time blocks 1-4
(see Figures 8 and 9,

effect,

left panels)

[atime block main

F(2, 271) = 398.90, p < 0.001].

U50488 Systemic Treatment
Overall,

(Time Blocks 5-8)

rats treated with U50488 showed

significantly greater locomotor activity than controls

when collapsed across time blocks 5-8
9, compare upper and lower panels)
F(l,

(see Figures 8 and

[pre-drug main effect,

110) = 39.26, p < 0.001]. This effect varied

according to time block, because the locomotion of
U50488-treated rats gradually increased across time blocks
5-8, while the locomotion of controls gradually declined

[apre-drug x time block interaction, F(2,

166) = 10.45,

p < 0.001].

Omnibus ANOVA Including SKF38393 and Quinpirole
Groups (Time Blocks 9-16)

An omnibus ANOVA assessing time blocks 9-16 resulted
in a significant three-way interaction
[apre-drug x post-drug x time block interaction,
F(27,

449) = 10.45, p < 0.001]. Because of the significant

interaction separate ANOVA's were conducted.
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Dorsostriatal SKF38393 Infusions
9-16)

(Time Blocks

Among rats infused with SKF38393, systemic
pretreatment with U50488 resulted in significantly greater

locomotor activity than saline
upper and lower right panels)

F(l,

(see Figure 8, compare

[pre-drug main effect,

56) = 78.32, p < 0.001], Specifically, locomotor

activity of U50488-pretreated rats increased over time
blocks 9-11 and then stabilized, while the locomotion of

saline-pretreated rats was minimal on all time blocks
[apre-drug * time block interaction, F(4, 220)
p < 0.001], SKF38393

(0,

10, 20, or 30 pg)

= 27.28,

infusions did

not affect locomotor activity on time blocks 9-16.
Dorsostriatal Quinpirole Infusions
9-16)

(Time Blocks

An overall ANOVA assessing the locomotor activity of
quinpirole-pretreated rats on time blocks 9-16 resulted in
a significant three-way interaction

[apre-drug x post-drug x time block interaction,
F(14, 258) = 8.35, p < 0.001], Because of the significant

interaction separate ANOVA's were conducted.

Dorsostriatal Quinpirole Infusions:
Saline-Pretreatment . Among rats pretreated with saline,

quinpirole

(10, 20, and 30 pg)

infusions significantly

augmented locomotor activity when compared to controls on
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time blocks 9-16

(see Figure 9, upper right panel)
F(3, 28)

[post-drug main effect,

= 13.66, p < 0.001;

apost-drug x time block interaction, F(12,
p < 0.001; Tukey HSD tests]. Furthermore,

111)

= 2.98,

rats infused

with 10 pg quinpirole exhibited greater locomotor activity

on time blocks 10-16 than rats infused with 20 or 30 pg

quinpirole

[Tukey HSD tests].

Dorsostriatal Quinpirole Infusions:
U50488-Pretreatment. When collapsed over time blocks 9-16,

quinpirole

(0,

10, 20, or 30 pg)

infusions did not

significantly alter the locomotor activity of
U5048.8-pretreated rats

(see Figure 9, lower right panel)

[post-drug main effect,

F(3, 28)

= 1.44, p > 0.05].

However, rats infused with quinpirole

(10, 20, and 30 pg)

showed a progressive decline in locomotor activity across
time blocks 9-11, while controls showed a progressive
increase across the same time blocks [apost-drug x time

block interaction, F(15,

138) = 9.85, p < 0.001; Tukey HSD

tests].
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5-Min Time Blocks

All rats were habituated to the testing chambers for 20 min (time blocks 1-4) and received
systemic injections of either saline or U50488 at the end of time block 4. All rats were infused
with SKF38393 (0, 10, 20, or 30 pg) at the end of time block 8 and immediately returned to the
testing chamber for an additional 40 min. Significantly different from rats in saline pre-drug
condition at the same time block (pre-drug x time block interaction). Significantly different
from rats given saline and SKF38393 (pre-drug main effect).______________________________

Figure 8. Mean Distance Traveled Scores of Rats Receiving
Infusions of SKF38393 during the Testing Session
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5-Min Time Blocks

All rats were habituated to the testing chambers for 20 min (time blocks 1-4) and received
systemic injections of either saline or U50488 at the end of time block 4. All rats were infused
with quinpirole (0, 10, 20, or 30 pg) at the end of time block 8 and immediately returned to the
testing chamber for an additional 40 min. Significantly different from rats in saline pre-drug
condition at the same time block (pre-drug x time block interaction). Significantly different
from rats given U50488 and 0 pg quinpirole (post-drug x time block interaction). Significantly
different from rats given saline and 0 pg quinpirole (post-drug main effect). “Significantly
different from rats given saline and 0, 20, or 30 pg quinpirole (post-drug main effect).________

Figure 9. Mean Distance Traveled Scores of Rats Receiving

Infusions of Quinpirole during the Testing Session
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CHAPTER TEN
DISCUSSION

The purpose of this thesis was to determine which
dopamine receptor subtype

(Dl or D2)

is responsible for

modulating the U50488-induced locomotor activity of

preweanling rats. It was predicted that a)

infusions of

the irreversible dopamine antagonist EEDQ into the dorsal
striatum would block NPA's ability to modulate

U50488-induced locomotion; and b)

but not quinpirole,

infusions of SKF38393,

into the dorsal striatum would block

U50488-induced locomotion.

Effects of U50488 on the Locomotor
Activity of Preweanling Rats

Systemic administration of U50488 increased the

locomotor activity of DMSO- and EEDQ-treated rats on PD 18

(see Figures 6 and 7, bottom middle panels). The ability
of kappa opioid agonists to enhance the locomotor activity

of preweanling rats and mice has been reported before

(Duke et al.,

1997; Karper, Nazarian, Crawford,

McDougall, 2000; Kehoe & Boylan,
1997,

1999)

Drago,

&

1994; McDougall et al.,

and is in sharp contrast to what, is observed

in adult animals.

Specifically, systemic administration of

a kappa opioid agonist decreases the locomotor activity,
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rearing., and grooming of adult rats
1988; Leyton & Stewart,

(Jackson & Cooper,

1992; Ukai & Kameyama,

1985). The

neuroanatomical basis for this age-dependent effect is not

fully understood, but it is known that U50488 induces
locomotor activity by stimulating kappa opioid receptors

in the substantia nigra pars reticulata

(Collins et al.,

2000; Zavala et al., 2002).

Effects of Dorsostriatal NPA Infusions
on U50488-Induced Locomotion

My results showed that infusing NPA into the dorsal
striatum dose-dependently attenuated U50488-induced

locomotor activity on PD 18

(see Figure 6, lower right

panel). When considered together with past studies
(Charntikov et al., 2008), it appears that stimulating

dorsostriatal D2 receptors is sufficient to attenuate the

kappa opioid-mediated locomotor activity of preweanling
rats. For various reasons, NPA's ability to cause a

dose-dependent reduction in U50488-induced locomotion
cannot be attributed to the onset of stereotypies.

First,

when NPA is given alone, either via striatal infusions or

systemic administration, locomotor activity and not
stereotypy is preferentially induced

(see Figure 6, upper

right panel; see also Charntikov et al., 2008). Second,

when NPA is coadministered with U50488 fewer stereotypies
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are evident than when NPA is administered alone

al., 1997; McDougall et al.,

(Duke et

1999).

Inability of EEDQ to Attenuate
NPA-Induced Behaviors
Contrary to our expectations, EEDQ pretreatment did
not attenuate NPA-induced behavioral effects.in

preweanling rats. For example, EEDQ/U50488-pretreated rats
showed greater locomotor activity than
DMSO/U50488-pretreated rats after intrastriatal infusions
of NPA. Second, NPA infusions did not reduce the locomotor

activity of U50488-treated rats but, instead, potentiated
U50488-induced locomotion. These results were

counterintuitive, because infusing EEDQ into the dorsal
striatum of adult rats significantly reduces dopamine

receptor content

(Giorgi & Biggio,

1990a). In any event,

the inability of EEDQ to block the NPA-induced behaviors
of preweanling rats means that EEDQ cannot be used as a

tool for determining which dopamine receptor subtype is
responsible for attenuating kappa opioid-mediated

locomotion. Instead,

I directly assessed this experimental

question by microinjecting selective Dl and D2 agonists
into the dorsal striatum of U50488- and saline-pretreated
rats.
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Effects of Dorsostriatal Infusions
of Dl and D2 Agonists
The results of Experiment 2A indicate that neither
quinpirole nor SKF38393, when infused into the dorsal

striatum, were able to attenuate the U50488-induced
locomotor activity of preweanling rats

(see Figures 8 and

9, lower right panels). The inability of SKF38393 to
inhibit U50488-induced locomotion was unexpected because
the striatonigral pathway, which is activated by striatal

Dl receptors, was hypothesized to modulate U50488-induced

locomotion

(Charntikov et al., 2008). The present

findings, however,

are consistent with adult rat studies

showing that striatal administration of SKF38393 does not
affect locomotor activity (Costall,

1984; Worms,

1986).

The inability of quinpirole to attenuate the
U50488-induced locomotor activity of preweanling rats was
expected because lesions of the indirect pathway, which is

disinhibited by D2 receptors, do not disrupt kappa
opioid-mediated locomotion (Charntikov et al., 2008). Even
so, these results are not consistent with a previous study
showing that systemic administration of quinpirole reduces

the U50488-induced locomotor activity of preweanling rats
(McDougall et al.,

1997). This disparity could be

explained by the regional non-selectivity of systemic drug
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administration. For example, quinpirole may activate
additional brain regions that comodulate the
U50488-induced locomotor activity of preweanling rats.
summary, contrary to my hypotheses,

In

selective activation

of Dl or D2 receptors in the dorsal striatum was unable to

attenuate the U50488-induced locomotor activity of

preweanling rats.

Neuronal Mechanisms Responsible for
Dopamine/Kappa Opioid Interactions
Systemic administration of a kappa opioid agonist

induces locomotor activity in preweanling rats by
activating postsynaptic kappa opioid receptors located on
neurons projecting from the substantia nigra pars

reticulata to the ventromedial thalamus and superior

colliculus

(Collins et al.,

2000; Zavala et al., 2002).

Evidence for this assertion is twofold:

first,

microinjecting a kappa opioid antagonist (e.g.,

nor-binaltorphimine) into the substantia nigra pars
reticulata fully attenuates U50488-induced locomotion

(Collins et al.,

2000). Second, lesions to the

ventromedial thalamus and superior colliculus abolish the

kappa opioid-mediated locomotor activity of preweanling
rats

(Zavala et al., 2002).
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The dopamine system modulates kappa opioid-mediated

locomotor activity, because dopamine agonists attenuate
U50488-induced locomotion when given systemically (NPA and
quinpirole)

or when infused into the dorsal striatum (NPA)

(Charntikov et al., 2008; Duke et al.,
al.,

1997,

1997; McDougall et

1999; Nazarian et al., 1999). Although the

mechanism responsible for this effect is not fully
understood, we have hypothesized that activation of

dopamine receptors

(Dl and D2)

in the dorsal striatum may

disinhibit GABAergic neurons proj ecting from the

substantia nigra pars reticulata to premotor areas. The
dopamine receptors modulating kappa opioid-mediated

locomotor activity do not appear to be a component of the
indirect striatonigral pathway. Evidence for this is

twofold: 1)

infusions of NPA into the dorsal striatum

attenuate U50488-induced locomotion, and 2)

lesioning key

areas of the indirect striatonigral pathway does not
disrupt this NPA-induced effect

(Charntikov et al., 2008).

Results of Experiment 1 and 2A demonstrated that

dorsostriatal administration of NPA, but not quinpirole or
SKF38393, attenuated the U50488-induced locomotor activity
of preweanling rats. Although quinpirole is selective for

the D2 receptor and SKF38393 is selective for the Dl

receptor, NPA is capable of stimulating both Dl and D2

94

receptors

(albeit NPA has greater affinity for D2

receptors). The different receptor affinities of these
drugs provides a potential explanation for the present
results, because it is well established that many

D2-mediated behavioral effects require the coactivation of

Dl receptors

(Canales & Iversen,

Dreher & Jackson,
Mrabet et al.,
regard,

1989; Fog,

1998; Colle & Wise,

1972; Kelly et al.,

1989; Solomon & Staton,

1982).

1991;

1975;

In this

it appears that Dl receptors have a "permissive"

or "enabling" effect

(Arnt,

1987; Braun & Chase,

1986).

Based on this explanation, I predict that coadministration
of quinpirole and SKF38393, either systemically or in the
dorsal striatum, would attenuate the U50488-induced

locomotor activity of preweanling rats.

Effects of Dorsostriatal Infusion of Quinpirole
on the Locomotor Activity of Preweanling Rats

Locomotor activity is not typically associated with

selective activation of dorsostriatal D2 receptors in
adult rats.

Instead, the majority of studies report that

infusing quinpirole

(3-40 pg)

into the dorsal striatum of

adult rats elicits behavioral sedation (i.e., reduced
locomotion and yawning)

Iversen,

(Bordi & Meller,

1998; Delfs & Kelley,

1989; Canales &

1990). The only exception

is a study showing a biphasic locomotor effect after
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quinpirole infusion

Meyer,

(Van Hartesveldt, Cottrell,

Potter,

&

1992). More specifically, Van Hartesveldt et al.

(1992) reported that lower doses

(10-20 pg)

of quinpirole

reduced locomotor activity, while higher doses

increased locomotion.

(40 pg)

Interestingly, adult rats are

capable of exhibiting intense forward locomotion after

dorsostriatal administration of quinpirole, but this
effect is only observed in dopamine denervated animals

(i.e., rats given 6-OHDA nigral lesions)

(LaHoste,

1990).

Contrary to these adult rat studies, we showed for
the first time that selective stimulation of D2 receptors

in the dorsal striatum is capable of eliciting significant
locomotor activity in preweanling rats. The ability of
quinpirole to augment the locomotor activity of

preweanling rats is consistent with data showing that

dorsostriatal infusions of NPA increase the locomotor
activity of preweanling rats

(see Figure 6, upper right

panel; Charntikov et al., 2008). This age-dependent
difference in responsivity to quinpirole is indicative of
ontogenetic differences in motor processing and regulation

within the striatonigral motor circuits of the basal

ganlia.
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Dorsostriatal Infusions: SKF38393

Infusions of SKF38393 into the dorsal striatum did
not affect locomotor activity of saline-pretreated rats on
PD 18. This effect is comparable to the behavioral

response observed in adult rats

1984b; Worms et al.,

(Costall, Kelly,

& Naylor,

1986). Therefore, we were able to

show for the first time that the locomotor activity of
preweanling rats, like adults,

is not affected by direct

stimulation of Dl receptors in the dorsal striatum.

Paradoxical Actions of EEDQ in Preweanling Rats

EEDQ pretreatment potentiated the locomotor activity
of NPA-treated rats in both the saline and U50488

conditions. There are several possible explanations for
these findings: First, EEDQ infusions into the dorsal
striatum may not have irreversibly inactivated D2

receptors.

Second,

striatal infusions of EEDQ may have

increased the sensitivity of the remaining D2 receptors.
Third,

EEDQ may have disproportionately inactivated one of

the dopamine receptor subtypes, thus creating an imbalance
in excitatory and inhibitory outputs from the striatum.
Fourth,

infusions of EEDQ into the dorsal striatum may

have disrupted the activity of acetylcholine medium spiny
neurons, which regulate activity of the striatonigral and
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striatopallidal pathways

& Zigmond,

(Galarraga et al.,

1999; Harsing

1998; Marti et al., 2003).

The first possibility (i.e., that EEDQ did not
inactivate a sufficient number of D2 receptors)

is not

very probable since previous studies have consistently
reported that EEDQ significantly reduces striatal dopamine

receptors in both adult and preweanling rats

al.,

1992,

Creese,

1994b,

1994c; Giorgi & Biggio,

(Crawford et

1990a; Hamblin &

1983). Although this is the first study to infuse

EEDQ into the striatum of preweanling rats, evidence from
adult studies suggests that this procedure should result
in a substantial decrease of dopamine receptors

(Giorgi &

Biggio, 1990a). More specifically, systemically

administered EEDQ reduces striatal dopamine receptors by

as much as 80-90% in adults, and 70-80% in preweanling
rats

(Crawford et al.,

1992,

1994c).

A second possibility, that striatal infusions of EEDQ
increased the sensitivity of either existing or newly

regenerated dopamine receptors, is only conjecture based
on dopamine denervation studies. Denervation of the

substantia nigra results in limited dopaminergic input to
the striatum (Calabresi, Mercuri, Sancesario,

& Bernardi,

1993). Denervated rats display a hyper-sensitive response

(10-40 fold more sensitive) to dopamine agonists
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(Marshall

& Ungerstedt,

1977; Schultz & Ungerstedt,

Fuxe, Agnati, Hokfelt,

1978; Schwarcz,

& Coyle, 1979; Thornburg & Moore,

1975). Because EDDQ inactivates a variety of monoamine
receptors,

it is conceivable that dorsostriatal EEDQ

infusions reduced dopamine levels in the striatum, thus
sensitizing dopamine receptors to NPA. It is also

conceivable that newly generated D2 receptors,

created as

a consequence of EEDQ treatment, would be super-sensitive.

Thus, NPA may induce a potentiated response in preweanling
rats because the remaining dopamine receptors are

super-sensitive.

A third possible explanation for EEDQ's potentiating

effect is that there is an imbalance in striatal Dl and D2
outputs. Excitatory (glutamate) and inhibitory (GABA)

projections to the major output areas

(substantia nigra

pars reticulata and internal globus pallidus)

of the basal

ganglia work in concert to execute a wide variety of motor

functions

(Canales & Iversen, 1998; Colle & Wise,

Dreher & Jackson,
Mrabet et al.,

Specifically,

1989; Fog,

1972; Kelly et al.,

1989; Solomon & Staton,

1991;
1975;

1982).

D2 receptor stimulation removes the

inhibition from the indirect pathway, while Dl receptor
stimulation activates the direct pathway.

It seems likely

that disproportional inactivation of Dl and D2 receptors
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by EEDQ would result in an imbalance of inputs affecting

the direct and indirect pathways. Moreover,

since most

studies report that EEDQ disproportionately inactivates Dl

and D2 receptors

Biggio,

1990a),

(Crawford et al.,

1992,

1994b; Giorgi &

it seems that this hypothetical D1/D2

imbalance could be responsible for EEDQ's paradoxical
behavioral effect.

A fourth possibility is that dorsostriatal EEDQ

infusions dramatically alter the activity of acetylcholine
neurons modulating striatal functioning. These medium
spiny interneurons, which innervate the striatum, provide

a powerful cholinergic signal that modulates striatal

output
et al.,

(Bernard, Dumartin, Lamy,

1994; Robertson, Vincent,

& Bloch,

1993; Di Chiara

& Fibiger,

1992).

Dopamine is the chief regulator of these cholinergic

interneurons

(Gerfen et al.,

1990). Specifically, nigral

dopaminergic output stimulates D2 receptors located on the
cell bodies of striatal cholinergic interneurons

(Claustre,

Fage, Zivkovic,

& Scatton,

1985). Stimulation

of these D2 receptors inhibits cholinergic output and, in

this way, alters the activity of GABAergic medium spiny

neurons that form the striatonigral and striatopallidal
pathways. Because EEDQ not only alters dopaminergic input,
but also inactivates acetylcholine receptors
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(Drazen &

Schneider,

Creese,

1978; Norman & Creese,

1989),

1986; Norman, Eubanks,

&

it is perhaps not surprising that EEDQ's

behavioral effects were not as predicted in the present

study.
In summary, it remains unclear why dorsostriatal

infusions of EEDQ did not diminish NPA's behavioral
effects in preweanling rats. Moreover, there is no

definitive explanation for why NPA caused a potentiated
locomotor response in EEDQ-pretreated rats. Although
unexplained, these results are consistent with previous

studies showing that systemic administration of EEDQ
attenuated the NPA-induced locomotor activity and
stereotypies of adult rats, while leaving the behaviors of

preweanling rats unaffected (McDougall et al.,
Mestlin & McDougall,

1993;

1993).

Conclusion

Contrary to our prediction, EEDQ did not block NPA's

ability to attenuate the kappa opioid-mediated locomotor
activity of preweanling rats. This result suggests that

selective inactivation of dopamine receptors utilizing

EEDQ cannot be achieved in preweanling rats.
infusions of selective dopamine agonists

Dorsostriatal

(SKF38393 and

quinpirole) did not attenuate U50488-induced locomotion.
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Thus,

it appears that a synergistic interaction between

dorsostriatal Dl and D2 receptors may be responsible for
attenuating the kappa opioid-mediated locomotor activity
of preweanling rats.
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